Indian Patents
Title of Invention

FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS
Abstract The present invention is related to novel furopyrimidinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA 1.
Full Text FORM 2
THE PATENT ACT, 1970
(39 Of 1970)
AND
THE PATENTS RULES, 2003
COMPLETE SPECIFICATION
(See section 10; rule 13)
1. TJTLE OF THE INVENTION:
"FUROPYR1MIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS"
2. APPLiCANT(S)
(a) Name: Glenmark Pharmaceuticals S.A.
(b) Nationality: Swiss
(c) Address: Chemin de la Combeta 5, 2300 La Chaux-de-Fonds, Switzerland.
3. PREAMBLE TO THE DESCRIPTION
COMPLETE
The following specification describes the The following specification particularly
invention describes the invention and the manner in
which it is to be performed.

FUROPYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS
Related applications
This application claims the benefit of Indian Patent Application Nos 665/MUM/2009 filed on March 23, 2009; 2213/MUM/2009 filed on September 23, 2009; 2906/MUM/2009 filed on December 16, 2009 and US Provisional Application Nos 61/171,355 filed on April 21, 2009; 61/251,994; filed on October 15, 2009 and 61/294,470 filed on January 12, 2010 all of which are hereby incorporated by reference.
Technical Field
The present patent application relates to furopyrimidinedione derivatives as TRPA1 modulators with transient receptor potential ankyrinl (TRPA1) activity.
Background of the Invention The transient receptor potential (TRP) channels or receptors are pain receptors. They have been classified into seven subfamilies: TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP (polycystin), TRPML (mucolipin), TRPA (ankyrin, ANKTM1) and TRPN (NOMPC) families. The TRPC family can be divided into 4 subfamilies (i) TRPC1 (ii) TRPC2 (iii) TRPC3, TRPC6, TRPC7 and (iv) TRPC4, TRPC5 based on sequence functional similarities. Currently the TRPV family has 6 members. TRPV5 and TRPV6 are more closely related to each other than to TRPV1, TRPV2, TRPV3 or TRPV4. TRPA1 is most closely related to TRPV3 and is more closely related to TRPV1 and TRPV2 than to TRPV5 and TRPV6. The TRPM family has 8 members. Constituents include the following: the founding member TRPM 1 (melastatin or LTRPC1), TRPM3 (KIAA1616 or LTRPC3), TRPM7 (TRP-PLIK, ChaK(l), LTRPC7), TRPM6 (ChaK2), TRPM2 (TRPC7 or LTRPC2), TRPM8 (TRP-p8 or CMR1), TRPM5 (MTR1 or LTRPC5) and TRPM4 (FLJ20041 or LTRPC4). The TRPML family consists of the mucolipins, which include TRPML1 (mucolipin 1), TRPML2 (mucolipin 2) and TRPML3 (mucolipin 3). The TRPP family consists of two groups of channels: those predicted to have six transmembrane domains and those that have eleven. TRPP2 (PKD2), TRPP3 (PKD2L1), TRPP5 (PKD2L2) are all predicted to have six transmembrane domains. TRPP1 (PKD1, PCI), PKD-REJ and PKD-1L1 are all thought to have eleven transmembrane domains. The sole mammalian member of the TRPA family is ANKTM1.

It is believed TRPAI is expressed in nociceptive neurons. Nociceptive neurons of the nervous system sense the peripheral damage and transmit pain signals. TRPAI is membrane bound and most likely acts as a heterodimeric voltage gated channel. It is believed to have a particular secondary structure, its N-terminus is lined with a large number of ankyrin repeats which are believed to form a spring-like edifice. TRPA1 is activated by a variety of noxious stimuli, including cold temperatures (activated at 17°C), pungent natural compounds (e.g., mustard, cinnamon and garlic) and environmental irritants (MacPherson, L. J. et al., Nature, 2007, 445; 541-545). Noxious compounds activate TRPAI ion channels through covalent modification of cysteines to form covalently linked adducts. Variety of endogenous molecules produced during tissue inflammation / injury have been identified as pathological activators of TRPAI receptor. These include hydrogen peroxide which is produced due to oxidative stress generated during inflammation, alkenyl aldehyde 4-HNE - an intracellular lipid peroxidation product and cyclopentenone prostaglandin 15dPGJ2 which is produced from PGD2 during inflammation / allergic response. TRPAI is also activated in receptor dependant fashion by Bradykinin (BK) which is released during tissue injury at peripheral terminals.
The difference between TRPAI and other TRP receptors is that TRPAI ligand binding persists for hours due to which the physiological response (e.g., pain) is greatly prolonged. Hence to dissociate the electrophile, an effective antagonist is required.
WO 2009/158719, WO 2009/002933, WO 2008/0949099, WO 2007/073505, WO 2004/055054 and WO 2005/089206 describe the TRP channels as the targets for the treatment of pain and related conditions.
In efforts to discover better analgesics for the treatment of both acute and chronic pain and to develop treatments for various neuropathic and nociceptive pain states, there exists a need for a more effective and safe therapeutic treatment of diseases, conditions and/or disorders modulated by TRPA1.
Summary of the Invention
The present invention relates to compounds of the formula (I):


or a pharmaceutically acceptable salt thereof, wherein,
R1 and R2, which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, arylalkyl, (CRxRy)nORx, C(0)RX C(0)ORx, C(0)NRxRy, (CH2)nNRxRy, (CH2)nCHRxRy, (CH2)nNRxRy and (CH2)nNHCORx;
R3 is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl. alkynyl, cycloalkyl, cycloalkylalkyl and cycloalkenyl;
Z1 and Z2 are independently oxygen or CRa: with a proviso that one of Z1 or Z2 is always oxygen and other is CRa;
L is a linker selected from -(CRKRy)n-, -0-(CRxRy)n-, -C(O) -NRx-; -S(0)mNRx-, -NRx(CRxRy)n- and -S(0)mNRx(CRxRy)n;
at each occurrence,Ra is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl. arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylalkyl, ORx, (CRxRy)nORx, C(0)Rx, C(0)ORx, C(0)NRxRy, S(0)mNRxRy, NRxRy, NRx(CRxRy)nORx, (CH2)n>JRxRy, (CH2)nCHRxRy, NRx(CRxRy)nC(0)NRxRy, (CH2)„NHC(0)Rx, (CH2)nNH{CH2)nS02Rx, (CH2)nNHS02Rx, SRx and ORx;
U is selected from -(CRxRy)n- substituted or unsubstituted aryl, substituted or unsubstituted five membered heterocycles selected from the group consisting of thiazole, isothiazole, oxazole, isoxazole, thiadiazole, oxadrazole, pyrazole, imidazole, furan, thiophene, pyrrole, 1,2,3-triazole and 1, 2, 4-triazole. or substituted or unsubstituted six membered heterocycle selected from the group consisting of pyrimidine, pyridine and pyridazine;
V is selected from hydrogen, cyano, nitro, -NRxRy, halogen, hydroxyl, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl. cycloalkylalkyl, cycloalkenyl, haloalkyl, haloalkoxy, cycloalkylalkoxy, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylalkyl, -C(0)ORx, -ORx, -C(0)NRxRy, -C(0)RN and -S02NRxRy; or
alternatively, U and V together may form an optionally substituted 3 to 7 membered. saturated or unsaturated cyclic ring that may optionally include one or more heteroatoms Selected from O, S and N;
at each occurrence, Rx and Ry are independently selected from hydrogen, hydroxyl,. halogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl.

cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylaikyl and
at each occurrence, 'm' and 'n' are independently selected from 0 to 2, both inclusive.
According to one embodiment, there is provided a compound of the formula (la):

or a pharmaceutically acceptable salt thereof, wherein,
R and R , which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, arylalkyl, (CRxRy)nOR*, C(0)Rx, C(O)ORx, C(O)NRxRy, (CH2)nNRxRy, (CH2)nCHRxRy, (CH2)nNRxRy and (CH2)nNHC(0)Rx;
Ra is selected from hydrogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylaikyl, ORx, (CRxRy)nORx, CORx, COORx, CONRxRy, S(0)mNRxRy, NRxRy, NRx(CRxRy)nORx, (CH2)nNRxRy, (CH2)nCHRxRy, NRx(CRvRy)nCONRxRy, (CH2)nNHCORx, (CH2)nNH(CH2)nS02Rx, (CH2)nNHS02Rx, SRx and ORx;
U is selected from -(CRxRy)n- substituted or unsubstituted aryl, substituted or unsubstituted five membered heterocycles selected from the group consisting of thiazole. isothiazole, oxazole, isoxazole, thiadiazole, oxadiazole. pyrazole, imidazole, furan, thiophene, pyrroles, 1,2,3-triazole and 1, 2, 4-triazole, or substituted or unsubstituted six membered heterocycle selected from the group consisting of pyrimidine, pyridine and pyridazine;
V is selected from hydrogen, cyano, nitro, -NRxRy, halogen, hydroxy!, substituted
or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl,
haloalkyl, haloalkoxy, cycloalkylalkoxy, aryl, arylalkyl, biaryl, heteroaryl,
heteroarylalkyl, heterocyclic ring and heterocyclylaikyl, -C(0)ORx, -ORx. -C(0)NRxRy, -C(0)Rx and -S02NRxRy; or

alternatively, U and V together may form an optionally substituted 3 to 7 membered saturated or unsaturated cyclic ring that may optionally include one or more heteroatoms selected from 0, S and N;
at each occurrence, Rx and Ry are independently selected from hydrogen, hydroxyl, halogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl. heterocyclic ring and heterocyclylalkyl and
at each occurrence, 'm' and 'n' are independently selected from 0 to 2, both inclusive.
The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
According to one embodiment, specifically provided are compound of the formula (la) in which Ra is hydrogen or (C1-C4) alkyl.
According to another embodiment, specifically provided are compound of the formula (la) in which R1 and R2 are methyl.
According to yet another embodiment, specifically provided are compound of the formula (la) in which 'U' is substituted or unsubstituted five membered heterocycle, preferably thiazole, imidazole, isoxazole, pyrazole or thiadiazole and the substituent are alkyl, halogen, haloalkyl, hydroxyalkyl and substituted or unsubstituted phenyl.
According to yet another embodiment, specifically provided are compounds of the formula (la) in which 'U' is substituted or unsubstituted six membered heterocycle, preferably pyridine.
According to yet another embodiment, specifically provided are compound of the formula (la) in which 'U' is substituted or unsubstituted aryl, preferably phenyl.
According to yet another embodiment, specifically provided are compound of the formula (la) in which 'U' is -CH2-CH2-linker.
According to yet another embodiment, specifically provided are compound of the formula (la) in which 'U' and 'V' are fused to form benzothiazole ring which is optionally substituted with one or more halogens.
According to yet another embodiment, specifically provided are compound of the formula (Ia) in which 'V is substituted or unsubstituted aryl, preferably phenyl. In this embodiment the substituents on phenyl may be one or more and are independently selected from; halogen (for example F, CI or Br), cyano. alkyl (for example iso-butyl or tert-butyl), haloalkyl (for example CF3), alkoxy (for example OCH3, OCH2CH(CH3)2,

OCH2C(CH3)3 or OCH2CH2CH(CH3)2), haloalkoxy (for example OCHF2, OCF3) OCH2CF3, or OCH2CH2CF3) and cycloalkylalkoxy (for example cyclopropylmethoxy). According to one embodiment, there is provided a compound of the formula (lb):

or a pharmaceutically acceptable salt thereof. wherein,
U, V. R1, R2 and Ra are as defined above.
The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
According to one embodiment specifically provided are compound of the formula (lb) in which Ra is hydrogen or (C1-C4) alkyl.
According to another embodiment, specifically provided are compound of the formula (lb) in which R1 and R2 are methyl.
According to yet another embodiment, specifically provided are compound of the formula (lb) in which 'U; is substituted or unsubstituted five membered heterocycle, preferably thiazole.
According to yet another embodiment, specifically provided are compounds of the formula (lb) iri which 'V' is substituted or unsubstituted aryl, preferably phenyl. In this embodiment the substituents on phenyl may be one Qr more and are independently selected from halogen (for example F, CI or Br), alkyl (CH2CH(CH3)2), haloalkyl (for example CF3)and haloalkoxy (for example OCHF2) OCF4 0r OCH2CF3).
According to one embodiment, there is provided a compound of the formula (Ic):


or a pharmaceutically acceptable salt thereof, wherein,
R1, R2 and Ra which may be the same or different, are each independently hydrogen or (Ci-C4)alkyl; and
R4, R5, R6, R7, R8 and R9, which may be same or different, are each independently selected from the group comprising of hydrogen, halogen, cyano, hydroxyl, nitro. amino, substituted or unsubstituted alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkylalkoxy, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylalkyl.
The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
According to one embodiment, specifically provided are compound of the formula (Ic) in which Ra is hydrogen or (C1-C4) alkyl, for example methyl.
According to another embodiment, specifically provided are compound of the formula (Ic) in which R1 and R2 are methyl.
According to another embodiment, specifically provided are compound of the
formula (Ic) in which R4, R5, R6 and R7 are independently selected from hydrogen, fluoro,
chloro, bromo. iso-butyl, 2,2-dimethylpropoxy, iso-butoxy, 3-methylbutoxy,
difluoromethxoy, trifluoromethyl trifluoromethoxy, trifluoroethoxy, trifluoropropoxy, and cyclopropylmethoxy.
According to yet another embodiment, specifically provided are compounds of the formula (Ic) in which R8 is hydrogen.
According to one embodiment, specifically provided are compounds of the formula (Ic) in which R9 are hydrogen or (C1-C4) alkyl.
Particularly contemplated are compound of the formulas (I), (la), (lb) and (Ic), which possess IC50 of less than 250 nM, preferably, less than 100 nM, more preferably, less than 50 hM with respect to TRPAI activity as measured by method as described in the present patent application.
It should be understood that the formulas (I), (la), (lb) and (Ic) structurally encompasses all stereoisomers, enantiomers and diastereomers, and pharmaceutically acceptable salts that may be contemplated from the chemical structure of the genera described herein.

The compound of the present invention as TRPA1 modulator is used herein because it is more selective for one TRP isoform than others, e.g., 2-fold, 5-fold, 10-fold, and more preferably at least 20, 40, 50, 60, 70, 80, or at least 100- or even 1000-fold more selective for TRPAI over one or more of TRPC6, TRPV5, TRPV6, TRPM8, TRPV1, TRPV2, TRPV4 and/or TRPV3.
In accordance with another aspect, the present patent application provides a pharmaceutical composition that includes at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or difuent}. Preferably, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. The compounds described in the present patent application may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
The compounds of the present invention can be administered as pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier. The ultimate dose will depend on the condition being treated, the route of administration and the age, weight and condition of the patient and will be the doctor's discretion.
Compounds of the present invention may be used in the manufacture of medicaments for the treatment of any diseases disclosed herein. The compounds and pharmaceutical compositions described herein are useful for modulating TRPAI receptors, wherein modulation is believed to be related to a variety of disease states.
The compound of the present invention can be administered alone or in -combination with other therapeutic agents. For instance, the TRPAI modulator is administered'Conjointly with one or more of an anti-inflammatory agent, anti-acne agent, anti-wrinkle agent, anti-scarring agent, anti-psoriatic agent, anti-proliferative agent, anti-fungal agent, anti-viral agent, anti-septic agent, anti-migraine agent, keratolytic agent, or a hair growth inhibitor.
In accordance with another aspect, the present patent application further provides a method of inhibiting TRPAI receptors in a subject in need thereof by administering to

the subject one or more compounds described herein in the amount effective to cause inhibition of such receptor.
Detailed Description of the Invention Definitions
The terms "halogen" or "halo'" includes fluorine, chlorine, bromine or iodine.
The term "alky!" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond. e.g.. methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl and 1,1-dimethylethyl (tert-butyl). The term "C1-6 alkyl" refers to an alkyl chain having 1 to 6 carbon atoms. Unless set forth or recited to the contrary, all alkyl groups described herein may be straight chain or branched, substituted or unsubstituted.
The term "alkenyl" refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be a straight or branched chain having 2 to about 10 carbon atoms, e.g., ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl. 2-methyl-l-propenyl. 1-butenyl and 2-butenyl. Unless set forth or recited to the contrary, all alkenyl groups described herein may be straight chain or branched, substituted or unsubstituted.
The term "alkynyl" refers to a straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and having 2 to about 12 carbon atoms (with radicals having 2 to about 10 carbon atoms being preferred) e.g., ethynyl, propynyl and butynyl. Unless set forth or recited to the contrary, all alkynyl groups described herein may be straight chain or branched, substituted or unsubstituted.
The term "alkoxy" refers to a straight or branched, saturated aliphatic hydrocarbon radical bonded to an oxygen atom that is attached to a core structure. Examples of alkoxy groups include but are not limited to methoxy. ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tert-butoxy, pentoxy, 3-methyl butoxy and the like. Unless set forth or recited to the contrary, all alkoxy groups described herein may be straight chain or branched, substituted or unsubstituted.
The term "haloalkyl" and "haloalkoxy" means alkyl or alkoxy, as the case may be, substituted with one or more halogen atoms, where alkyl and alkoxy groups are as defined above. The term "halo" is used herein interchangeably with the term "halogen" means F, C1, Br or I. Examples of "haloalkyl" include but are not limited to

trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, pentachloroethyl
4,4,4-trifluorobutyl, 4,4-difluorocyclohexyl. chloromethyl, dichloromethyl,
trichloromethyl, 1-bromoethyl and the like. Examples of "haloalkoxy" include but are not
limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy,
pentafluoroethoxy, pentachloroethoxy, chloromethoxy, dichloromethoxy,
trichloromethoxy, 1-bromoethoxy and the like. Unless set forth or recited to the contrary, all "haloalkyl" and "haloalkoxy" groups described herein may be straight chain or branched, substituted or unsubstituted.
The term "cycloalkyl" denotes a non-aromatic mono or multicyclic ring system of 3 to about 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups or sprirobicyclic groups, e.g., spiro(4,4)non-2-yl. Unless set forth or recited to the contrary, all cycloalkyl groups described herein may be substituted or unsubstituted.
The term "cycloalkylalkyl" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms directly attached to an alkyl group. The cycloalkylalkyl group may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Non-limiting examples of such groups include cyclopropylmethyl, cyclobutylethyl and cyclopentylethyl. Unless set forth or recited to the contrary, all cycloalkylalkyl groups described herein may be substituted or unsubstituted.
The term "cycloalkylalkoxy"' is used to denote alkoxy substituted with cycloalkyl, wherein 'alkoxy' and 'cycloalkyl' are as defined above (either in the broadest aspect or a preferred aspect). Examples of cycloalkylalkoxy groups include cyclopropylmethoxy, 1-or 2-cyclopropylethoxy, 1-, 2- or 3- cyclopropylpropoxy, 1-, 2~, 3- or 4-cyclopropyl-butoxy, cyclobutylmethoxy, 1- or 2- cyclobutylethoxy, 1-, 2- or 3- cyclobutylpropoxy, 1-, 2-, 3- or 4-cyclobutylbutoxy, cyclopentylmethoxy, 1- or 2-cyclopentylethoxy, 1-, 2- or 3-cyclopentylpropoxy, K 2-, 3- or 4- cyclopentylbutoxy, cyclohexylmethoxy, 1- or 2-cyclohexylethoxy and 1-, 2- or 3- cyclohexylpropoxy. Preferably, 'cycloalkylalkoxy' is (C3-6)cycloalkyl-(C1-6)alkoxy. Unless set forth or recited to the contrary, all cycloalkylalkoxy groups described herein may be substituted or unsubstituted.
The term "cycloalkenyl" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms with at least one carbon-carbon double bond, such as

cyclopropenyl, cyclobutenyl and cyclopentenyl. Unless set forth or recited to the contrary, all cycloalkenyl groups described herein may be substituted or unsubstituted.
The term "aryl" means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be fused. If the rings are fused, one of the rings must be fully unsaturated and the fused ring(s) may be fully saturated, partially unsaturated or fully unsaturated. The term 'fused" means that a second ring is present (i.e., attached or formed) by having two adjacent atoms in common (i.e., shared) with the first ring. The term "fused" is equivalent to the term "condensed". The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Unless set forth or recited to the contrary, all aryl groups described herein may be substituted or unsubstituted.
The term "arylalkyl" refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH2C6H5 or -C2H4C6H5. Unless set forth or recited to the contrary, all arylalkyl groups described herein may be substituted or unsubstituted. The term "heterocyclic ring" refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring systems, which may include fused, bridged or spiro ring systems and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heterocyclic or heteroaryl). Examples of such heterocyclic ring radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazolyl, imidazolyl, tetrahydroisoquinolyl, piperidinyl. piperazinyl. 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl,' pyrrolidinyl. pyrazinyl. pyrimidinyl, pyridazinyl. oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl. thiazoly], thiazolinyl. thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl. quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl. thiadiazolyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl. thienyl, benzothienyl,

thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, dioxaphospholanyl, oxadiazolyl, chromanyl and isochromanyl. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a .stable structure. Unless set forth or recited to the contrary, all heterocyclic ring described herein may be substituted or unsubstituted.
The term "heterocyclyl" refers to a heterocyclic ring radical as defined above. The heterocyclyl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described herein may be substituted or unsubstituted.
The term "heterocyclylalkyl" refers to a heterocyclic ring radical directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclylalkyl groups described herein may be substituted or unsubstituted.
The term "heteroaryl" refers to an aromatic heterocyclic ring radical. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heteroaryl groups described herein may be substituted or unsubstituted.
The term "heteroarylalkyl" refers to a heteroaryl ring radical directly bonded to an alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heteroarylalkyl groups described herein may be substituted or unsubstituted.
Unless otherwise specified, the term "substituted" as used herein refers to substitution with any one or more or any combination of the following substituents: hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl. substituted or unsubstituted cycloalkenyialkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstiuted

guanidine, -C(0)ORx', -C(0)Rx', -C(S)RX', -C(0)NRxRy', -C(0)ONRxRy', -NRvC(0)NRy'R2', -N(Rx')SORy', -N(Rx')S02Ry', -(=N-N(Rx')Ry), -NRx'C(0)ORy', -NRxRy, -NRx'C(0)Ry", -NRx'C(S)Ry', -NRx'C(S)NRy'Rz'! -SONRxRy', -S02NRxRy', -ORx', -ORx'C(0)NRi"Rz') -ORx'C(0)ORy', -OC(0)Rv'; -OC(0)NRxRy', -Rx'NRy'C(0)Rz', -R^'OR*', -Rx'C(0)ORy", -Rx'C(0)NRy,Rz", -RxC(0)Ry', -Rx'OC(0)Ry', -SRx', -SORx', -S02Rx' and -ON02) wherein Rx', Ry and Rz are independently selected from hydrogen, substituted or unsubstituted alky], substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted ary], substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted' ary], substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl or substituted or unsubstituted heterocyclic ring.
The term "treating" or "treatment" of a state, disorder or condition includes; (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e.. arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
The term "subject" includes mammals (especially humans) and other animals, such as domestic animals (e.g.. household pets including cats and dogs) and non-domestic animals (such as wildlife).
A "therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to effect such treatment. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.
The compounds described in the present patent application may form salts. Non-limiting examples of pharmaceutically acceptable salts forming part of this patent application include salts derived from inorganic bases salts of organic bases, salts of chiral bases, salts of natural amino acids and salts of non-natural amino acids.

Certain compounds of the present invention, including compounds of formula (1), (la), (lb) and (Ic) are capable of existing in stereoisomeric forms (e.g. diastereomers and enantiomers). The present invention includes these stereoisomeric forms (including diastereomers and enantiomers) and mixtures of them. The various stereoisomeric forms of the compounds of the present invention may be separated from one another by methods known in the art or a given isomer may be obtained by stereospecific or asymmetric synthesis. Tautomeric forms and mixtures of compounds described herein are also contemplated.
Pharmaceutical Compositions
The pharmaceutical composition of the present patent application includes at least one compound described herein and at least one pharmaceutically acceptable excipient (such as a pharmaceutically acceptable carrier or diluent). Preferably, the pharmaceutical composition includes the compound(s) described herein in an amount sufficient to inhibit TRPA1 in a subject (e.g., a human). The inhibitory activity of compounds falling within the formulas (I), (la), (lb) and (Ic) may be measured by an assay provided below.
The compound of the present invention may be associated with a pharmaceutically acceptable excipient (such as a carrier or a diluent) or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
The pharmaceutical compositions may be prepared by techniques known in the art. For example, the active compound can be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container, for example, in a sachet.
The pharmaceutical compositions may be in conventional forms, for example, capsules, tablets, aerosols, solutions, suspensions or products for topical application.
Methods of Treatment
The compounds and pharmaceutical compositions of the present invention can be administered to treat any disorder, condition, or disease treatable by inhibition of TRPAI. For instance, the compounds and pharmaceutical compositions of the present invention are suitable for treatment or prophylaxis of the following diseases, conditions and

disorders mediated or associated with the activity of TRPA1 receptors: pain, chronic pain-complex regional pain syndrome, neuropathic pain, postoperative pain, rheumatoid arthritic pain, osteoarthritic pain, back pain, visceral pain, cancer pain, algesia, neuralgia, migraine, neuropathies, chemotherapy - induced neuropathies, eye - irritation, bronchial - irritation, skin - irritation (atopic dermatitis), frost - bites (cold - bite), spasticity, catatonia, catalepsy, parkinsons. diabetic neuropathy, sciatica, HIV-related neuropathy, post-herpetic neuralgia, fibromyalgia, nerve injury, ischaemia, neurodegeneration, stroke, post stroke pain, multiple sclerosis, respiratory diseases, asthma, cough, COPD, inflammatory disorders, oesophagitis, gastroeosophagal reflux disorder (GERD), irritable bowel syndrome, inflammatory bowel disease, pelvic hypersensitivity, urinary incontinence, cystitis, burns, psoriasis, eczema, emesis, stomach duodenal ulcer and pruritus. The connection between therapeutic effect and inhibition of TRPA1 is illustrated, for example, in Story, G. M. et al. Cell, 2003, 112, 819-829; McMahon, S.B. and Wood, J. N, Cell, 2006, 124, 1123-1125; Voorhoeve, P. M. et al. Cell, 2006, 124, 1169-1181: Wissenbach, U, Niemeyer, B. A. and Flockerzi, V. Biology of the Cell, 2004. 96, 47-54; and the references cited therein.
Pain can be acute or chronic. While acute pain is usually self-limiting, chronic pain persists for 3 months or longer and can lead to significant changes in a patient's personality; lifestyle, functional ability and overall quality of life (K. M. Foley, Pain, in Cecil Textbook of Medicine; J. C. Bennett & F. Plum (eds.), 20th ed, 1996, 100-107). The sensation of pain can be triggered by any number of physical or chemical stimuli and the sensory neurons which mediate the response to this harmful stimulus are termed as "nociceptors". Nociceptors are primary sensory afferent (C and A5 fibers) neurons that are activated by a wide variety of noxious stimuli including chemical, mechanical, thermal and proton (pH Chronic pain can be classified as either nociceptive or neuropathic. Nociceptive pain includes tissue injury-induced pain and inflammatory pain such as that associated with arthritis. Neuropathic pain is caused by damage to the sensory nerves of the peripheral Or central nervous system and is maintained by aberrant somatosensory processing. The pain is typically well localized, constant and often with an aching or

throbbing quality. Visceral pain is the subtype of nociceptive pain that involves the internal organs. It tends to be episodic and poorly localized. Nociceptive pain is usually time limited, meaning when the tissue damage heals, the pain typically resolves (arthritis is a notable exception in that it is not time limited).
General Methods of Preparation The compound of the general formula (1). (la), (lb) and (1c) and specific examples
to demonstrate embodiments of the invention can be prepared by methods described
below in schemes 1-8. However, those skilled in the art should, in light of the methods
described herein, can prepare these compounds through similar approaches without
departing from the spirit and scope of the invention. Furthermore, in the following
synthetic schemes, where specific acids, bases, reagents, coupling agents, solvents, etc.
are mentioned, it is understood that other suitable acids, bases, reagents, coupling agents
etc. may be used and are included within the scope of the present invention. The
compounds obtained by using the general reaction sequences may be of insufficient
purity. These compounds can be purified by using any of the methods for purification of
organic compounds known to persons skilled in the art, for example, crystallization or
silica gel or alumina column chromatography using different solvents in suitable ratios.
All possible stereoisomers are envisioned within the scope of this invention.
A general approach for the synthesis of furopyrimidinyl acetamides of the general
formula (I), wherein Z1, Z2, R1, R2, R3, U, V and L are as defined above in description is
described in .-scheme 1. Coupling reaction of the compounds of the formula (1) (wherein R
is hydrogen or alkyl) with amines of the formula (2) in the presence of a suitable coupling
agent such as I-ethyI-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (EDCI) and
base in suitable solvent gives compounds of the formula (3). The selective N-alkylation of
the compounds of the formula (3) where X is halogen, with suitable alkylating agent of
the formula (4) in the presence of base in a suitable solvent gives compound of the
general formula (I).


A general approach for the synthesis of furo[2.3-d]pyrimidinyl acetamides of
formula (la) wherein Ra is hydrogen and U, V, R1 and R2 are as defined above is as
shown is scheme 2. Coupling reaction of 1,3-dialkylbarbituric acid derivative of the
formula (5) with chloroacetyl chloride derivative (6) in the presence of a suitable base
like sodium hydride and in a suitable solvent like THF gives 5-(chloroacetyl)-6-hydroxy-
l,3-dialkylpyrimidine-2,4(lH3H)-dione as an intermediate which on cyclisation in the
presence of triethyfamine gives furo[2,3-d]pyrimidinetrione of formula (7). A similar
approach is described by Strekowski, L. et al in ./. Heterocyclic Chem. 2001, 38, 359-
363. Furo[2,3-d]pyrimidinetrione compounds of formula (7) was converted into furo[2,3-
d]pyrimidinedione ester of compounds of general formula (8) by reaction with the
lithium salt of ethyl acetate (generated from dry ethyl acetate and Lithium
bis(trimethylsilyl)amide [LHMDS]) followed by dehydration and isomerization under
acidic conditions. Direct coupling of compounds of the general formula (8) with
appropriate amines of formula (2) by using suitable base (e.g., sodium hydride) and in
suitable solvent (e.g. toluene, tetrahydrofuran) gives compounds of the general formula
(la). Alternatively, compounds of the general formula (la) can be prepared in two steps
by hydrolysis of (8) under basic conditions to give the carboxylic acid (9) followed by
coupling with amine of the general formula (2) using a suitable coupling agents [e.g., N-
ethy]-N'-(3-dimethyLaminopropyL) carbodiimide hydrochloride (EDO), benzotriazol-]-
yloxytris (dimethylamino) phosphonium hexafluorophosphate [BOP] in suitable solvent
or mixture of solvents (e.g., N,N-dimethyl formamide, tetrahydrofuran, dichloromethane
etc. to give/compound of the general formula (la).
Scheme 2


Alternatively, the carboxylic acid intermediate of the general formula (9) can be prepared as described in scheme 3, wherein R1 and R2 are as defined above. Thus, reaction of cyanomethyl lithium with furo[2,3-d]pyrimidinetrione of formula (7) (where Ra is hydrogen or alkyl) in a suitable solvent gives furo[2.3-d]pyrimidinyl acetonitrile of the formula (10). This intermediate on hydrolysis under acidic conditions gives intermediate of the formula (9) required for the synthesis of compounds of the general formula (Ta).
Furo[2.3-d]pyrimidinedione ester of the formula (8a) where Ra is hydrogen or alkyl can also be prepared through a Wittig reaction on intermediate (7) as shown in scheme 4; wherein R and R are as defined above. Thus, reaction of intermediate (7) with trimethyl phosphonoacetate in the presence of a suitable base such as sodium hydride, potassium tert-butoxide or n-butyl lithium in suitable solvent (e.g., tetrahydrofuran, dimethyl sulfoxide) gives ester of the formula (11). The ester (II) is then isomerized under acidic conditions to give intermediates of the formula (8a) useful for the preparation of compounds of the present invention represented by the formula (la).

Another approach for the preparation of intermediates of the general formula (8b) is given in scheme 5, wherein R1 and R2 are as defined above. Thus. Reformatsky reaction on intermediate (7) (where Ra is hydrogen or alkyl) by using BrZnCH2OO2R where R is alkyl (prepared from Zn and BrCH2CO2R) followed by in-situ dehydration of the carbinol intermediate gives intermediate (12). Double bond isomerization of intermediate (12) under acidic conditions gives the ester intermediate (8b).


General approach for the synthesis of compound of formula (Ic) (wherein Ra is hydrogen or methyl and R1, R2, R4, R5, R6, R7, R8 and R9 are as defined above) is depicted in scheme 6. Direct coupling of compounds of the general formula (8) with appropriate amines of formula (23) by using suitable base (e.g., sodium hydride) and in suitable solvent (e.g. toluene, tetrahydrofuran) gives compound of the general formula (1c). Alternatively, compounds of the general formula (lc) can be prepared in two steps by hydrolysis of (8) under basic conditions to give the carboxylic acid (9) followed by its coupling with amine of the general formula (23) using a suitable coupling agents [e.g., N~ ethyl-/V'-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI), benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate [BOP]) in suitable solvent or mixture of solvents (e.g., N,N-dimethyl formamide, tetrahydrofuran, dichloromethane etc. to give compounds of the general formula (Ic).

A general approach for the synthesis of furo[3,4-d]pyrimidinyl acetamides of formula (lb) wherein Ra, U, V, Rl and R2 are as defined above is as shown in scheme 7. 5-MethylAH~furo[3,4-d][l,3]oxazine-2,40H)-dione of the formula (13) can be prepared according to the procedure described by Press, J. B., et al, Eur. J, Med. Chem. 1989, 24,

627-630 starting from dialkyl 2-methy]furan-3,4-dicarboxylate. The intermediate of the formula (1) is treated with alkyl amine of the formula R'-NI-h to give the urea derivative (14) through a ring opening reaction. Cyclisation of intermediate (14) using 1,1'-carbonyldiimidazole (CDI) in suitable solvent followed by alkylation with R2X in the presence of a suitable solvent gives 3,5-dialkylfuro[3,4-a[]pyrimidine-2,4(lH,3H)-dione of the formula (16) via intermediate (15). Intermediate (16) is deprotonated with a strong base such as sodium hydride or n-butyl lithium and reacted with dialkyl carbonate to give the ester (17). Coupling reaction of ester of the formula (17) with appropriate amines of formula (2) in the presence of a suitable base such as sodium hydride in the presence of suitable solvent such as dry toluene or xylene gives compound of general formula (lb).

A general approach for the synthesis of substituted 2-amino-4-aryl thiazole of the formula (23) (wherein R4, R5, R6, R7, R8 and R9 are as defined above) from benzoic acid derivative is given in scheme 8. Thus, benzoic acid of formula (18) was converted to the corresponding acid chloride of formula (19) using oxalyl chloride in the presence of catalytic amounts of DMF in dry dichioromethane. The acid chloride of formula (19) was converted to corresponding Weinerb amide of formula (21) by treating with N.O-dimethyl hydroxyl amine hydrochloride of formula (20) in the presence of a suitable base such as triethylamine. The addition of methyl magnesium iodide to Weinreb amide of formula (21) afforded acetophenone derivative of formula (22).
Conversion of acetophenone derivative of formula (22) to 2-amino-4-aryl thiazole of the formula (23) can be effected by two approaches (scheme 8). In the first case acetophenone was converted to the corresponding phenacyl bromide, which in turn was reacted with thiourea in a suitable solvent such as tetrahydrofuran at refluxing condition. Alternatively, acetophenone derivative of formula (22) can be converted to 2-amino-4-aryl thiazole (23) in one step by its reaction with thiourea and iodine in refluxing ethanol

(Carroll, K. et al. J. Am. Chem. Soc. 1950, 3722 and Naik, S. J.; Halkar, U. P., ARKIVOC 2005, xiii, 141-149).

Experimental Unless otherwise stated, work-up includes distribution of the reaction mixture between the organic and aqueous phase indicated within parentheses, separation of layers and drying the organic layer over sodium sulphate, filtration and evaporation of the solvent. Purification, unless otherwise mentioned, includes purification by silica gel chromatographic techniques, generally using ethyl acetate/petroleum ether mixture of a suitable polarity as the mobile phase. Use of a different eluent system is indicated within parentheses. The following abbreviations are used in the text: DMSO-d6 Hexadeuterodimethyl sulfoxide; DMF: N,N-dimethyl form amide; J: Coupling constant in units of Hz: RT or rt: room temperature (22-26°C); Aq.: aqueous; AcOEt: ethyl acetate; equiv. or eq.: equivalents.
Intermediates Intermediate 1 Ethyl (l,3-diniethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetate

Step 1: Ethyl (22)-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5(6H)-ylidene)acetate or Ethyl (5-hydroxy-l,3-dimethyl-2,4-dioxo-l,2,3,4,5,6-hexahydrofuro[2,3-d]pyrimidin-5-yl)acetate: Anhydrous THF (50.0 ml) was cooled to -78°C. A solution of lithium bis(trimethylsilyl)amide (LiHMDS) (1.0 M in THF, 4.692 g, 28.038 mmol) was added under nitrogen atmosphere. Then, dry ethyl acetate (2.358 g, 26.763 mmol) was added and the resulting mixture was stirred at the same temperature

for 1 h. A solution of l,3-dirnethylfuro[2.3-d]pyrimidine-2.4,5(lH,3H,6H}-trione (5.0 g, 25.489 mmol) in a mixture of THF and dichloromethane (1:3. 80.0 ml) was added dropwise to the above solution and the resulting mixture was stirred at -78°C for 2.5 h. The reaction mixture was then acidified with IN HC1 (75.0 ml). The temperature was allowed to rise gradually until reaching room temperature and was extracted with ethyl acetate. The organic extract was washed with brine (50.0 ml), dried over anhydrous Na2SO4 and filtered. The filtrate was evaporated under reduced pressure and the residue obtained was purified with column chromatography by using 2 % methanol in chloroform to obtain 2.1 g of ethyl (2Z)-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5(6H)-ylidene)acetate as a white solid; *H NMR (300 MHz, CDC13) 5 1.29 (t, J= 12 Hz, 3H), 3.35 (s, 3H), 3.45 (s, 3H), 4.17 (q, J= 7.5 Hz, 2H), 6.37 (s, 1H). Further elution with increasing amounts of methanol in chloroform gives 750 mg of ethyl (5-hydroxy-13-dirnethyl-2,4-dioxo-l,2,3,4,'5,6-hexahydrofuro[2,3-d]pyrimidin-5-yl)acetate as a light brown solid; lH NMR (300 MHz, CDC13) 5 1.33 (t, J= 7.2 Hz, 3H), 3.39 (s, 3H), 3.54 (s, 3H); 4.08 (s, 2H), 4.27 (q, J = 7.5 Hz; 2H), 4.77 (s, 1H); APCJ-MS (m/z) 267.09 (M+H)+.
Step 2: Ethyl (],3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetate: A mixture of step 1 intermediate (1.1 g, 4.131 mmol) and glacial acetic acid (20.0 ml) was refluxed for 4 h. Excess of acid was evaporated under vacuum and the residue obtained after evaporation of the solvent was purified by silica gel column chromatography using 2 % methanol in chloroform to obtain 930 mg of the product as a white solid; lH NMR (300 MHz, CDC13) 8 1.19 (t, J= 7.5 Hz, 3H); 3.18 (s, 3H), 3.41 (s, 3H), 3.68 (s, 2H), 4.09 (q, J= 12 Hz, 2H), 7.58 (s, 1H); APCI-MS (m/z) 267.13 (M+H)+.
Intermediate 2 (l,3-Dimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)aceticacid

To a stirred solution of Intermediate I (150 mg, 0.563 mmol) in a mixture of THF (2.0 ml) and water (1.0 ml) was added LiOH.H2O (36 mg, 0.845 mmol). The mixture was stirred for 30min. at room temperature. Residue obtained after evaporation of the solvent was acidified with 1 N HCl (pH 4) and extracted with ethyl acetate (2 x 50 ml). The combined ethyl acetate extract was washed with water (2x15 ml) and dried (Na2S04).

Evaporation of solvent under reduced pressure afforded 70 mg of the product as an off-white solid; l-H NMR (300 MHz, CDC13) 6 3.19 (s, 3H), 3.50 (s, 3H), 3.60 (s, 2H), 7.56 (s, JH), 12.43 (brs, 1H); APCI-MS (m/z) 239.06 (M+H)+.
Intermediate 3 Ethyl (l,3,6-trimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetate

The title compound was prepared according to the procedure described in Intermediate 1 by using 1;3,6-trimethylfuro[2,3-d]pyrimidine-2,4;5(lH,3H;6H)-trione (5.0 g, 23.788 mmol) in the place of l;3-dimethylfuro[2,3-d]pyrimidine~2,4,5(lH,3H,6H)-trione in the first step to give 1.565 g of the product as a white solid; ]H NMR (300 MHz, CDC13) 5 1.28 (t J= 7.5 Hz, 3H), 2.28 (s, 3H), 3.35 (s, 3H), 3.52 (s, 3H), 3.64 (s, 2H), 4.19 (q, j= 7.2 Hz, 2H); APCI-MS (m/z) 281.05 (M+H)+.
Intermediate 4 (1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[23-^pyrimidin-5-yl)acetic acid

Saponification of Intermediate 3 (150 mg, 0.535 mmol) using LiOH (34 mg, 0.802 mmol) in a mixture of THF (4.0 ml) and water (1.0 ml) as described in Intermediate 2 afforded 60 mg of the title compound as a white solid: 1H NMR (300 MHz, CDCI3) 5 2.27 (s, 3H), 3.17 (s, 3H), 3.39 (s, 3H), 3.55 (s, 2H), 12.32 (br s, 1H); APCI-MS (m/z) 253.09 (M+H)+.
General procedure for the preparation of 2-amino-4-arvl thiazoles: Method 1:
A solution of acetophenone derivative (1.0 equiv) in glacial acetic acid (5 vol) was added liquid bromine (1.0 equiv) at 0°C and reaction mixture was stirred at room temperature for 2h. The reaction mixture was diluted with water and extracted with ethyl acetate, washed with brine and dried over Na2SO4. The crude product obtained upon concentration was dissolved in dry THF (10 volumes) and thiourea (2.0 equiv) was added and refluxed overnight. The reaction mixture was diluted with ethyl acetate, washed with

sodium thiosulfate solution and organic layer was treated with IN HC1 to result in salt formation of the amine. The precipitated salt was collected by filtration. The salt was then treated with saturated solution of NaHC03 to re-generate the amine. The mixture was extracted with dichloromethane (2 x 50 ml) and the combined organic extracts were washed with water and brine. The solvent was evaporated under reduced pressure to afford the 2-amino-4-aryl thiazole derivative. Method 2:
A solution of acetophenone derivative (1.0 equiv.), thiourea (2.0 equiv.) and iodine (1.0 equiv.) in dry ethanol (5 volumes) was refluxed for 24 h. The reaction mixture was diluted with ethyl acetate and the layer was separated. The organic layer was washed with sodium thiosulfate solution to remove iodine. The ethyl acetate solution was treated with IN HCI and precipitated salt collected by filtration. The free amine was re-generated as described in method 1 given above.
All,the 2-amino-4-aryl thiazole derivatives were prepared by either method 1 or method 2 starting from appropriate aryl alkyl ketones. Structure information and characterization data for selected intermediates are given in Table 1.
Table 1: Structural details and 'H NMR data of selected 2-aminothiazole intermediates









Further it should also be noted that several fluoro substituted 2-amino-4-aryl thiazole can be prepared using the approach described in scheme 8 by following method 1 or method .2 starting from appropriate fluorinated benzoic acid or fluroninated acetophenone. A few examples of such aminothiazole intermediates are given in Table 2.
Table 2: Structure of fluoro substituted 2-amino-4-arylthiazole

SNo Structure Name Mol. Formula (Mol.
Wt.)




For further illustration of methods of preparing the compounds of the present invention, the following examples are disclosed below.
Examples
General proceaure Method A:
To a stirred solution of appropriate amine (1.2 equiv.) in dry toluene, sodium hydride (1.4 equiv.) was added and after stirring for 30 min at room temperature, furopyrimidinyl acetic acid ester derivative (1.0 equiv.) was added and heated to reflux for 48 h. The reaction mixture was concentrated and the residue obtained was acidified to pH 6.0 by addition of IN hydrochloric acid and extracted with ethyl acetate. The combined organic layers were dried (Na2SO4). The residue obtained after evaporation of the solvent was purified by silica gel column chromatography using suitable ethyl acetate and petroleum ether mixture to obtain the desired products. Method B:
To a stirred solution of furopyrimidinyl acetic acid derivative (1.0 equiv.) in 1,2-dichloroethane (5 vol.) was added EDCI (1.2 equiv.), HOBt (0.3 equiv.) and 4-dimethylaminopyridine (0.1 equiv.) and the mixture was stirred at room temperature for 10-15 min. An appropriate amine (1.0 equiv.) was added and mixture was stirred at the same temperature for 48 h. Excess of solvent was evaporated and the residue obtained was diluted with ethyl acetate and 2 N HC1. Two layers were seperated. The organic layer was washed with water, brine, dried (Na2SO4) and filtered. The filtrate was concentrated under reduced pressure and the residue obtained was purified by silica gel column chromatography using 30 % ethyl acetate in petroleum ether to afford the desired compound.
Example 1 N\ -[4-(4-Trifluorornethylphenoxy)phenyl]-2-( 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofurb[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method B) by coupling Intermediate 2 (60 mg, 0.252 mmol) with 4-[4-(trifluoromethyl)phenoxy]ani!ine (64 mg, 0.252 mmol) in the presence of EDCI hydrochloride (58 mg, 0.302 mmol), HOBt (10 mg, 0.075 mmol) and DMAP (3.1 mg, 0.025 mmol) in U-dichloroethane (5 ml) to give 17 mg;of the product as a white solid; !H NMR (300 MHz, DMSCM6) 8 3.20 (s, 3H), 3.43 (s,'3H), 3.74 (s, 2H), 7.06-7.13 (m, 4H), 7.60-7.73 (m, 5H), 10.27 (br s, 1H): APCI-MS (m/z) 474.40 (M+H)+.
Example 2 M-^-Cl^-DichlorophenylJethylJ^-tl^-dimethyl^^-dioxo-l^J^-tetrahydrofuropj-]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method B) by coupling Intermediate 2 (100 mg, 0.420 mmol) with 2-(2,4-dichlorophenyl)ethanamine (79 mg, 0.415 mmol) in the presence of EDCI hydrochloride (96 mg. 0.504 mmol), HOBt (17 mg, 0,126 mmol) and DMAP (5 mg, 0.042 mmol) in 1,2-dichloroethane (5 ml) to give 10 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 5 2.81 (t,J = 6.6 Hz, 2H), 3.18 (s, 3H)S 3.40-3.46 (m, 7H), 7.28 (s, 2H), 7.52 (d, J= 8.7 Hz, 2H), 8.02 (br s, 1H); APCI-MS (m/z) 410.21 (M+H)+.
Example 3 Nl-[4-(Trifluoromethyl)-l,3-thiazol-2-yl]-2-(l,3-Dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(trifluoromethyl)-l,3-thiazol-2-

amine (60 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 40 mg of the product as an off-white solid: ]H NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H), 3.42 (s, 3H), 3.87 (s, 2H), 7.63 (s, 1H), 7.95 (s, 1H), 12.77 (br s, 1H); APCI-MS (m/z) 388.99 (M+H)+.
Example 4 A'-(4,6-Difluoro-l,3-benzothiazol-2-yl)-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2.3-a]pyrimidin-5-yI)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg. 0.375 mmol) with 4.6-difluoro-I,3-benzothiazol-2-amine (83.mg. 0.450 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 8 mg of the product as an off-white solid; 'H NMR (300 MHz. DMSO-40 5 3:17 (s, 3H), 3.43 (s, 3H), 3.92 (s, 2H), 7.39 (t; J= 9.6 Hz, 1H), 7.65 (s, 1H), 7.79 (d,J= 7.8 Hz, 1H), 12.85 (brs, 1H); APCI-MS (m/z) 407.11 (M+H)+.
Example 5 Nl-[4-(4-Isobutylphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-],2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yI)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(4-isobutylphenyl)-l,3-thiazol-2-amine (84 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene' (10 ml) to give 25 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-40 6 0.88 (d, J= 6.3 Hz, 6H), 1.82-1.90 (m, 1H), 3.18 (s, 3H), 3.43 (s, 3H), 3.87 (s, 2H), 7.21 (d, J= 7.8 Hz, 2H), 7.54 (s, 1H), 7.63 (s, 1H), 7.81 (d, J = 7.8 Hz, 2H), 12.44 (br s, 1H); APCI-MS (m/z) 453.16 (M+H)+.
Example 6

Nl-{4-[4-(Trifluoromethyl)phenyl]-l,3-thia2ol-2-yl}-2-(1,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetarnide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (75 mg, 0.282 mmol) with 4-[4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (83 mg. 0.338 mmol) in the presence of sodium hydride (28 mg, 0.705 mmol) in dry toluene (10 ml) to give 20 mg of the product as an off-white solid; lHNMR (300 MHz, DMSO-4i) 5 3.17 (s, 3H), 3.43 (s, 3H), 3.89 (s, 2H), 7.64 (s, 1H), 7.78-7.96 (m, 3H), 8.09-8.15 (m, 2H), 12.55 (br s, 1H); APCI-MS (m/z) 465.11 (M+H)+.
Example 7 An-{4-[3-(Trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-K2;3,4-tetrahydrofuro[2,3-^pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg. 0.300 mmol) with 4-[3-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (88 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 16 mg of the product as an off white solid; 'H NMR (300 MHz, DMSO-d6) δ 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s: 2H), 7.60-7.72 (m, 3H)5 7.88 (s, 1H), 8.20-8.26 (m, 2H), 12.54 (br s, 1H); APCI-MS (m/z) 465.32 (M+H)+.
Example 8 Nl-[4-(4-TrifIuorormethoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d][pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate I (75 mg, 0.282 mmol) with 4-[4-(trifluoromethoxy)phenyI]-I,3-thiazol-2-amine (88 mg, 0.338 mmol) in the presence of sodium hydride (28 mg, 0.705

mmol) in dry toluene (10 ml) to give 11 mg of the product as an off-white solid; H NMR (300 MHz, DMSO-d6) 6 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.43 (d, J= 8.4 Hz, 2H), 7.62 (s, IH), 7.69 (s, IH), 8.02 (d, J = 9.0 Hz, 2H), 12.47 (br s, 1H); APC3-MS (m/z) 481.14 (M+H)+.
Example 9 N1 -[4-(3-Trifluororrnethoxyphenyl)-l ,3-thiazol-2-yl]-2-( 1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg. 0.300 mmol) with 4-[3-(trifluoromethoxy)phenyl]-l,3-thiazoI-2-amirie (93 mg. 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 60 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-40 δ 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.33 (d, J = 7.8 Hz, IH), 7.54-7.64 (m; 2H), 7.82 (s, 1H), 7.87 (s, 1H), 7.95 (d, J= 7.8 Hz, 1H), 12.52 (br s, 1H); ESI-MS (m/z) 481.21 (M+H)+.
Example 10 Nl-[4-(3-Bromo-4-fluorophenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(3-bromo-4-fluorophenyl)-l,3-thiazol-2-armne (98 mg, 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 16 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3M (s, 2H), 7.45 (t, J= 8.7 Hz, 1H), 7.62 (s, 1H), 7.74 (s, 1H), 7.81-7.88 (m, 1H), 8.23 (d, J= 6.9 Hz, 1H), 12.45 (br s, 1H); APC1-MS (m/z) 491.36 (M-H):
Example 11

M-[4-(3,4-Difluorophenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetarnide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(3,4-difluorophenyl)-l,3-thiazol-2-amine (77 mg. 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 40 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.51 (q, J= 8.7 Hz, 1H), 7.63 (s, 1H), 7.70-7.76 (m, 2H), 7.87-7.96 (m, 1H), 12.49 (br s, 1H); APCI-MS (m/z) 433.06 (M+H)+.
Example 12 N1-[4-(2,4-Difluorophenyl)-I,3-thiazol-2-yl]-2-(I,3-dimethyI-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate I (80 mg, 0.300 mmol) with 4-(2,4-difIuorophenyl)-1,3-thiazoI-2-amine (76 mg. 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 29 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.40 (s, 3H), 3.86 (s, 2H), 7.20 (t, J= 9.6 Hz, 1H), 7.34-7.41 (m, 1H), 7.47(s.. 1H), 7.61 (s, 1H), 8.06 (q, J= 7.5 Hz: 1H), 12.53 (br s, 1H); APCI-MS (m/z) 433.05 (M+H)+.
Example 13 N1-[4-(3,4-Dichlorophenyl)-1,3-thiazonal-2-yl]-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4 tetrahydrofuro[2,3-d]pyininidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.375 mmol) with 4-(3,4-dichlorophenyl)-l,3-thiazol-2-amine (] 10 mg, 0.450 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 17 mg of the product as a white solid; lH NMR (300 MHz. DMSO-d6)S 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.63 (s, 1H), 7.70 (d, J = 8.1 Hz, 1H), 7.83 (s, 1H), 7.89 (d, .J= 8.4 Hz, 1H), 8.14 (s, 1H), 12.48 (br s, 1H): APCI-MS (m/z) 463.20 (M-HV
Example 14 Nl-{4-[3-Fluoro-4-(trifluoromethyl)phenyl3-1,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg. 0.375 mmol) with 4-[3-fluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (118 mg, 0.450 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 25 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3.89 (s, 2H), 7.63 (s, 1H), 7.86 (t, J= 7.8 Hz, 1H), 7.92-8.02 (m, 3H), 12.55 (br s, 1H); APCI-MS (m/z) 481.25 (M-H)'
Example 15 Nl-{4-[4-FIuoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l;2,3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate I (100 mg, 0.375 mmol) with 4-[4-fluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (136 mg, 0.518 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 25 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s,

2H), 7.55-7.65 (m, 2H), 7.84 (s, 1H), 8.23-8.29 (m, 2H), 12.51 (br s, 1H); APC1-MS (m/z) 481.27 (M-H)"
Example 16 Nl-{4-[4-Fluoro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo~1,2,3.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.375 mmol) with 4-[4-fluoro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (125 mg; 0.450 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 26 mg of the product as a white solid; JH NMR (300 MHz, DMSO-d6) 6 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.55-7.63 (m, 2H), 7.79 (s, 1H), 7.97-8.05 (m, 2H), 12.49 (br s, 1H): ESI-MS (m/z) 497.24 (M-H).
Example 17 Nl-{4-[3-Fluoro-4-(trifluoromethoxy)phenyl]-],3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl) acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (56 mg, 0.210 mmol) with 4-[3-fluoro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-amine (70 mg, 0.252 mmol) in the presence of sodium hydride (21 mg, 0.525 mmol) in dry toluene (10 ml) to give 37 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.62-7.69 (m, 2H), 7.84 (s, 2H), 7.95-8.01 (m, 1H), 12.54 (br s, 1H); ESI-MS (m/z) 497.26 (M+H)+
Example 18 N1 -{4-[4-Chloro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl }-2-( 1,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.375 mmol) with 4-[4-chloro-3-(trifluoromethyl)phenyl]-l,3-thiazoN2-amine (126 mg, 0.450 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 26 mg of the product as a white solid; ]H NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H); 3.43 (s, 3H), 3.88 (s, 2H), 7.58-7.64 (m, 1H), 7.80 (d, J= 8.1 Hz, 1H), 7.92 (s, 1H), 8.20 (d, J= 7.8 Hz, 1H), 8.34 (s, 1H), 12.54 (br s, 1H); APCI-MS {m/z) 499.00 (M+H)+.
Example 19 N\ -{4-[4-ChIoro-3-(trifluoromethoxy)phenyl]-I ,3-thiazol-2-yl]-2-( 1,3-dimethyI-2,4-dioxo-l,2,3.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[4-chIoro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (100 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 32 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.62 (s,, 1H), 7.76 (d, J= 8.7 Hz, 1H), 7.87 (s, 1H), 7.93-8.04 (m, 2H), 12.51 (br s, 1H); APCI-MS (m/z) 513.23 (M-H)-.
Example 20 Nl-{4-[2-Fluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate I (80 mg, 0.300 mmol) with 4-[2-fluoro-3-(trifluoromethyl)phenyl]-1.3-thiazol-2-amine (94 mg, 0.360 mmol) in the presence of

sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 50 mg of the product as an off-white solid; 'H NMR (300 MHz; DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3.89 (s, 2H), 7.53 (d, J= 7.8 Hz, 1H), 7.63 (s, 1H), 7.68 (s, 1H), 7.77 (t J= 6.9 Hz, 1H), 8.33 (tJ= 7.5.Hz, 1H), 12.55 (br s, 1H); APCI-MS (m/z) 481.26 (M-H)
Example 21 Nl-{4-[3-FIuoro-5-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2.3.4-tetrahydrofuro[23-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-fluoro-5-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (94 mg, 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 25 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) & 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.60-7.68 (m, 2H), 7.98-8.15 (m, 3H), 12.54 (br s, 1H): APCI-MS (m/z) 481.24 (M-
H)Example 22 Nl-{4-[2-Fluoro-4-(trifluoromethyl)phenyl]-1.3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-t/Jpyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[2-fluoro-4-(trifluorome4hyl)phenyl]-l,3-thiazol-2-amine (94 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 30 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3.90 (s, 2H)S 7.63 (s,.lH), 7.73 (s, 2H), 7.78-7.84 (m, 1H), 8.23-8.29 (m, 1H), 12.56 (br s, 1H); APCI-MS (m/z) 483.07 (M+H)+.
Example 23

N1-[4-(3-Fluoro-4-difluoromethoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(3-fluoro-4-difluoromethoxyphenyl)-l,3-thiazol-2-arnine (95 mg, 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 10 mg of the product as an off-white solid; ]H NMR (300 MHz, DMSO-d6) 6 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.01 (t, J= 73.2 Hz, 1H), 7.44 (t,J= 8.4 Hz, 1H), 7.63 (s, 1H), 7.73-7.81 (m, 2H), 7.85-7.91 (m, 1H), 12.49 (br s, 1H); APCI-MS (m/z) 479.23 (M-H)
Example 24 Nl-[4-(3-Chloro-4-difluoromethoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydromro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-chloro-4-(difluoromethoxy)phenyl]-l,3-thiazoI-2-amine (99 mg, 0.360 mmol) in the presence of sodium hvdride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 50 mg of the product as an off-white solid; lH NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.32 (t, J= 73.2 Hz, 1H), 7.45 (d, J= 9.0 Hz, 1H), 7.63 (s, 1H), 7.77 (s, 1H), 7.93 (d, J=8.7Hz, 1H), 8.10 (s, 1H), 12.49 (br s, 1H); APCI-MS (m/z) 497.16 (M+H)+.
Example 25 ATI -[4-(3-Bromo-4-difluoromethoxyphenyl)-1,3-thiazol-2-yI]-2-( 1,3-dimethyI-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-(/|pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-bromo-4-(difluorormethoxy)phenyl]-l,3-thiazol-2-amine (116 mg, 0.360 mmol) in the presence of sodium hydride (24 mg, 0.600 mmol) in dry toluene (10 ml) to give 27 mg of the product as an off-white solid; !H NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H), 3.43 (s, 3H), 3.87 (s, 2H), 7.33 (t,J= 73.2 Hz, 1H), 7.40 (d, J= 8.1 Hz, 1H), 7.63 (s, IH), 7.77 (s, 1H), 7.93-7.99 (m, IH), 8.26 (s, 1H), 12.50 (br s, 1H); APCI-MS (m/z) 541.20 (M+H)+.
Example 26 Nl-{4-[4-(2;2-DimethyIpropoxy)-3-fluorophenyl]-1,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-3,2,3,4-tetrahydrofuro[2,3-d]pynmidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg. 0.300 mmol) with 4-[4-(2.2-dimethylpropoxy)-3-fluorophenyl]-l,3-thiazol-2-amine (101 mg. 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 27 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 1.02 (s, 9H), 3.18 (s, 3H), 3.43 (s, 3H), 3.74 (s, 2H), 3.87 (s, 2H), 7.22 (t, J = 8.1 Hz, IH), 7.56 (s, IH), 7.62 (s, IH), 7.65-7.70 (m, 1H),7.73-(SS1H), 12.43 (brs, IH); APCI-MS (m/z) 501.15 (M+H)+.
Example 27 Nl-{4-[3-Chloro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-chloro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazoI-2-amine (107 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 54 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 8 1.04 (s, 9H), 3.18 (s, 3H), 3.43 (s,

3H), 3.75 (s, 2H), 3.87 (s, 2H), 7.18 (d, J= 8.4 Hz, IH), 7.58 (s, IH), 7.62 (s, IH), 7.77-7.85 (m, 1H), 7.95(s, 1H), 12.42 (br s,1H); APCI-MS (m/z) 517.10 (M+H)+.
Example 28 N1-{4-[3-Bromo-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazoI-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-bromo-4-(2.2-dimethylpropoxy)phenyI]-I,3-thiazoI-2-amine (122 mg, 0.360 mmol) in the presence of sodium hydride (30 mg. 0.750 mmol) in dry toluene (10 ml) to give 26 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 1.05 (s, 9H), 3.17 (s, 3H), 3.43 (s, 3H), 3.75 (s, 2H), 3.87 (s, 2H), 7.14 (d, J= 8.7 Hz, 1H), 7.58 (s, 1H), 7.62 (s, 1H), 7.86 (d, J= 7.8 Hz, 1H), 8.12 (s, 1H), 12.43 (br s, 1H): APCI-MS (m/z) 561.06 (M)+.
Example 29 N1 -[4-(3-Bromo-4-isobutoxyphenyl)-l,3-thiazol-2-yl]-2-(l;3-dimethyl-2,4-dioxo-l ,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(3-bromo-4-isobutoxyphenyl)-1,3-thiazoI-2-amine (118 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 40 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 1.02 (d, J =6.6 Hz, 6H), 2.02-2.08 (m, 1H), 3.18 (s, 3H), 3.43 (s, 3H), 3.87 (s, 4H), 7.15 (d, J= 9.0 Hz, 1H), 7.58 (s, 1H), 7.62 (s, 1H), 7.85 (d,J= 8.7 Hz, lH):8.12(s, 1H), 12.42 (br s, 1H); APCI-MS (m/z) 547.09 (M)+.
Example 30 Nl-{4-[3-Fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-fluoro-4-(2,2,2-trifluoroethoxy)pheny]]-l,3-thiazol-2-amine (105 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 23 mg of the product as a white solid; lH NMR (300 MHz, DMSO-d6) 5 3.16 (s, 3H), 3.41 (s, 3H), 3.86 (s, 2H), 4.87 (q, J= 8.7 Hz, 2H), 7.34 (t, J= 8.7 Hz, 1H), 7.61 (s, 2H), 7.68-7.73 (m, 2H), 12.41 (brs, lH);APCI-MS(w/z) 513.07 (M+H)+.
Example 31 N1-{4-[3-Chloro-4-(2,2,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate I (80 mg, 0.300 mmol) with 4-[3-chloro-4-(2,2,2-trifluoroethOxy)phenyl]-l,3-thiazol-2-amine (111 mg, 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 34 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) δ 3.18 (s, 3H), 3.43 (s, 3H), 3.87 (s, 2H), 4.91 (d, J = 8.7 Hz, 2H), 7.35 (d,J= 8.7 Hz, 1H), 7.62 (s, 1H), 7.66 (s, 1H), 7.86 (d, .J = 9.0 Hz, 1H),8.01 (s, 1H), 12.43 (brs, 1H); APCI-MS (m/z) 529.15 (M+H)+.
Example 32 Nl-{4-[3-Bromo-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}2-(l:3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-bromo-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-amine (127 mg, 0.360 mmol) in the presence of

sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 53 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.18 (s, 3H), 3.43 (s, 3H), 3.87 (s, 2H), 4.90 (q,J= 8.7 Hz, 2H), 7.31 (d,J=8.7Hz, 1H), 7.62 (s, 1H), 7.66 (s, 1H):7.91 (d, J=9.3Hz, lH),8.16(s, 1H), 12.43 (brs, 1H); APCI-MS (m/z) 51X21 (M-H)".
Example 33 N1-[4-(2,4,5-Trifluromethyl)-1,3-thiazol-2-yl]-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the genera) procedure (Method A) by coupling Intermediate 1 (80 mg. 0.300 mmol) with 4-(2.4,5-trifluorophenyl)-l,3-thiazol-2-amine (83 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 20 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 3.J 7 (s, 3H), 3.43 (s, 3H), 3.89 (s, 2H), 7.59 (s, 1H), 7.63 (s, 1H), 7.70-7.76(m, 1H), 7.88-8.00 (m, 1H), 12.53 (brs, 1H): APCI-MS (m/z) 451.18 (M+H)+.
Example 34 Nl-[4-(2,3,4-Trichlorophenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuror2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(2,3,4-trichlorophenyl)-l,3-thiazol-2-amine (100 mg, 0.429 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 30 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) δ 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.63 (s, 1H), 7.68 (s, 1H), 7.80 (d,J=8.7Hz, 2H), 12.51 (brs, 1H); APCI-MS (m/z) 499.39 (M-H)".
Example 35 N1-{4-[2,4-Difluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.375 mmol) with 4-[2,4-difluoro-3-(trifluorornethyl)phenyl]-l,3-thiazol-2-amine (126 mg, 0.450 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 30 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6.) 6 3.18 (s, 3H), 3.43 (s, 3H), 3.89 (s, 2H), 7.47-7.56 (m, 1H), 7.63 (s, 2H), 8.33 (q,J= 6.6 Hz, 1H), 12.54 (br s, 1H);APCI-MS (m/z) 499.39 (M-H)
Example 36 Nl-{4-[3,5-Difluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yI)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3,5-difluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (100 mg, 0.360 mmol) in the presence of sodium hydride (30 mg. 0.750 mmol) in dry toluene (10 ml) to give 20 mg of the product as an off-white solid; !H NMR (300 MHz, DMSO-d6) δ 3.17 (s, 3H), 3.43 (s, 3H), 3:89 (s, 2H), 7.63 (s, 1H), 7.84 (s, 1H), 7.88 (s, 1H), 8.09 (s; 1H), 12.59 (br s, IH): APCI-MS (m/z) 500.97 (M+H)+,
Example 37 Nl-{4-[3,5-Difluoro-4-(difiuoromethoxy)phenyI]-l;3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3,5-difluoro-4-

(difluoromethoxy)phenyl]-].3-thiazol-2-amine (100 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.751 mmol) in dry toluene (10 ml) to give 25 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-40 5 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.27 (t,.J= 71.7 Hz, 1H), 7.62 (s, 1H), 7.79 (d, J= 9.3 Hz, 2H), 7.88 (s, 1H), 12.51 (br s, 1H); APCI-MS (m/z) 499.00 (M+H)+.
Example 38 Nl-{4-[3,5-Dichloro-4-(difluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3,5-dichloro-4-(difluoromethoxy)phenyl]-l,3-thiazol-2-amine (112 mg, 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 15 mg of the product as an off-white solid: 1H NMR (300 MHz, DMSO-d6) 6 3.18 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 7.19 (t. J = 72.3 Hz, 1H), 7.63 (s, 1H), 7.94 (s, 1H), 8.12 (s, 2H), 12.51 (br s, 1H); APCI-MS (m/z) 529.21 (M-H)
Example 39 N-{4-[4-(Cyclopropylmethoxy)-3,5-difluorophenyl]-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[4-(cyclopropylmethoxy)-3,5-difluorophenyl]-l,3-thiazo]-2-amine (102 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 50 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 0.23-0.30 (m, 2H), 0.50-0.56 (m, 2H), 1.88-1.94 (m, 1H), 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 3.97 (d, J= 7.2 Hz, 2H), 7.60-7.68 Cm. 3H) 7.74 (s, 1H), 12.46 (br s, 1H); APCI-MS (m/z) 503.11 (M+H)+.

Example 40 N1-{4-(3,5-Difluoro-4-isobutoxyphenyl)-l,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(3,5-difluoro-4-isobutoxyphenyl)-l,3-thiazol-2-amine (102 mg. 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 26 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 5 0.98 (d, J =6.9 Hz, 6H), 1.93-2.04 (m, 1H), 3.18 (s, 3H), 3.43 (s, 3H), 3.86-3.93 (m, 4H), 7.60-7.68 (m, 3H), 7.73 (s, 1H), 12.45 (br s, 1H); APCI-MS (m/z) 503.29 (M-H)
Example 41 N1-[4-(3,5-Dichloro-4-isobutoxyphenyl)l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-],2.3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-(3,5-dichloro-4-isobutoxyphenyl)-1,3-thiazol -2-amine (114 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 20 mg of the product as an off-white solid; !H NMR (300 MHz, DMSO-d6) 5 1.04 (d, J= 6.9 Hz, 6H), 2.00-2.14 (m, IH), 3.17 (s, 3H), 3.43 (s, 3H), 3.79 (d, 7-5.7 Hz, 2H), 3.87 (s, 2H), 7.63 (s, IH), 7.82 (s, IH), 8.00 (s, 2H), 12.48 (br s, IH); APCI-MS {m/z) 537.09 (M+H)+.
Example 42 Nl-{4-[3,5-Difluoro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d](pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (75 mg, 0.282 mmol) with 4-[4-(2,2-dimethylpropoxy)-3,5-difluorophenyl]-l,3-thiazol-2-amine (101 mg, 0.338 mmol) in the presence of sodium hydride (28 mg, 0.704 mmol) in dry toluene (10 ml) to give 38 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6) 6 1.01 (s, 9H), 3.18 (s, 3H), 3.43 (s, 3H), 3.80 (s, 2H), 3.88 (s, 2H), 7.60-7.66 (m, 3H), 7.73 (s, 1H), 12.45 (br s, 1H); APCI-MS (m/z)519.14(M+H)+.
Example 43 N-{4-[3,5-Dichloro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazo]-2-y]}-2-(1,3-dimethyl-2,4-dioxo-l 2.3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate I (80 mg, 0.300 mmol) with 4-[3,5-dichloro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-amine (119 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 16 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 1.23 (s, 9H), 3.17 (s, 3H), 3.43 (s, 3H), 3.67 (s, 2H), 3.88 (s, 2H), 7.63 (s, IH), 7.83 (s, IH), 8.00 (s, 2H), 12.49 (br s, IH); APCI-MS '(m/z) 551.09 (M+H)+.
Example 44 Nl-{4-[3-Chioro-5-fluoro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2.3a4-tetrahydrofuro[2,3-d]pynmidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-chloro-5-fluoro-4-(2,2-dimethylpropoxy)phenyI]-l,3-thiazol-2-amine (113 mg. 0.360 mmol) in the presence of sodium hydride (36 mg, 0.900 mmol) in dry toluene (10 ml) to give 50 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 5 1.04 (s, 9H), 3.17 (s, 3H), 3.43 (s, 3H), 3.78 (s, 2H), 3.88 (s, 2H), 7.62 (s, 1H), 7.75-7.81 (m, 2H), 7.85 (s, 1H), 12.46 (br s, 1H); APCJ-MS (m/z) 535.26 (M+H)+.
Example 45 N1 -{4-[3,5-Difluoro-4-(3-methylbutoxy)phenyl]-1,3-thiazol-2-yl }-2-( 1,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3,5-difluoro-4-(3-methylbutoxylphenyl]-l,3-thiazol-2-amine (107 mg, 0.358 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 40 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) § 0.92 (d, J= 6.3 Hz, 6H), 1.59 (q, J= 6.3 Hz, 2H): 1.88-1.93 (m, 1H), 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 4.15 (6,J = 6.6 Hz, 2H), 7.60-7.69 (m, 3H), 7.75 (s, 1H), 12.49 (br s, 1H); ESI-MS (m/z) 519.11 (M+H)+.
Example 46 Nl-{4-[3,5-Difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l;3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-3,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling, Intermediate 1 (75 mg, 0.282 mmol) with 4-[3,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-amine (105 mg, 0.338 mmol) in the presence of sodium hydride (28 mg, 0.704 mmol) in dry toluene (10 ml) to give 28 mg of the product

as a white solid; 1H NMR (300 MHz, DMSO-d6) 6 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 4.85 (q, J= 8.7 Hz, 2H), 7.62 (s, 1H), 7.70 (d, J= 93 Hz, 2H), 7.80 (s, IH), 12,48 (br s, 1H); APCI-MS (m/z) 531.08 (M+H)+.
Example 47 N1-{4-[3,5-Dichloro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl)2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrabydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3,5-dichloro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-amine (123 mg, 0.360 mmol) in the presence of sodium hydride (36 mg.. 0.900 mmol) in dry toluene (10 ml) to give 17 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 8 3.17 (s, 3H), 3.43 (s, 3H), 3.88 (s, 2H), 4,75 (q, J= 8.7 Hz, 2H), 7.62 (s, 1H), 7.87 (s, 1H), 8.04 (s, 2H), 12.48 (br s, 1H); APCI-MS {m/z) 563.06 (M+H)+.
Example 48 Nl-{4-[3-ChIoro-5-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (80 mg, 0.300 mmol) with 4-[3-chloro-5-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-amine (117 mg, 0.360 mmol) in the presence of sodium hydride (30 mg, 0.750 mmol) in dry toluene (10 ml) to give 22 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 3.17 (s, 3H), 3.43 (s, 3H)S 3.88 (s, 2H), 4.83 (q, ./= 8.7 Hz, 2H), 7.62 (s. 1H), 7.80-7.92 (m, 3H), 12.48 (br s, 1H); APCI-MS (m/z) 545016 (M-H)'.
Example 49

Nl-{4-[3,5-Difluoro-4-(3,3,3-trifluoropropoxy)phenyl]-l,3-thiazol-2-yl}-2-(1,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2-3-d]pyrimidin-5-yl]acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (57 mg, 0.216 mmol) with 4-[3,5-difluoro-4-(3,3,3-trifluoropropoxy)phenyl]-l,3-thiazoI-2-amine (70 mg, 0.216 mmol) in the presence of sodium hydride (22 mg, 0.540 mmol) in dry toluene (10 ml) to give 17 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 8 2.74-2.83 (m, 2H), 3.17 (s, 3H), 3.43 (s, 3H), 3.8.8 (s,2H), 4.30-4.38 (m, 2H), 7.60-7.69 (m, 3H), 7.76 (s, 1H), 12.47 (br s, 1H); APCI-MS (m/z) 543.18 (M-H)".
Example 50 Nl-{4-t4-(Trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.177 mmol) with 4-[4-(trifluoromethyl)phenyl]-1.3-thiazol-2-amine (51 mg, 0.212 mmol) in the presence of sodium hydride (11 mg, 0.442 mmol) in dry toluene (10 ml) to give 32 mg of the product as a white solid: 1H NMR (300 MHz, DMSO-d6) δ 2.32 (s, 3H), 3.16 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.78-7.86 (m, 3H), 8.12 (d, J= 8.4 Hz, 2H), 12.50 (br s, 1H); APCI-MS (m/z) 479.14 (M+H)+.
Example 51 Nl-{4-[3-(Tr.ifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.177 mmol) with 4-[3-(trifluoromethyI)phenyI]-I,3-thiazol-2-amine (51 mg. 0.212 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 30 mg of the product as a white solid; 'H NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.16 (s, 3H), 3.42 (s, 3H), 3.83 (s, 2H), 7.66-7.74 (m, 2H), 7.87 (s, l.H), 8.19-8.26 (m, 2H), 12.49 (br s, 1H): APCI-MS (m/z) 479.16 (M+H)+.
Example 52 Nl-{4-[3-(Trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.177 mmol) with 4-[3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (55 mg. 0.212 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 12.5 mg of the product as a white solid; 'H NMR (300 MHz,:DMSO-d6) 6 2.32 (s, 3H), 3.16 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.30-7.36 (m, 1H), 7.58 (t, J= 7.8 Hz, 1H), 7.81 (s, 1H), 7.87 (s, 1H), 7.95 (d, 7= 7.8 Hz, IH), 12.48 (brs, 1H); APCI-MS (m/z) 495.11 (M+H)+.
Example 53 Nl-{4-[4-(Trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(1.3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[4~(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (55 mg, 0.214 mmol) in the presence of sodium hydride (10 mg, 0.445 mmol) in drytoluene (10 ml) to give 30 mg of the product as a white solid; ]H NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.16 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H); 7.44 (d, J= 7.8 Hz, 2H), 7.69 (s, IH), 8.02 (d, J= 8.7 Hz, 2H), 12.46 (br s, 1H); APCI-MS {m/z) 495.11 (M+H)+

Example 54 Nl-[4-(3,4-Dichlorophenyl)-l,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (40 mg, 0.142 mmol) with 4-(3.4-dichlorophenyl)-l,3-thiazol-2-amine (42 mg, 0.171 mmol) in the presence of sodium hydride (14 mg, 0.355 mmol) in dry toluene (10 ml) to give 25 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6,) δ 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s: 2H), 7.21 (d, J= 8.1 Hz, IH), 7.83 (s, IH), 7.89 (d, J= 8.7 Hz, IH), 8.15 (s, IH), 12.47 (br s, 1H);APCI-MS (m/z) 479.09 (M+H)+.
Example 55 Nl-[4-(2,3-Dichlorophenyl)-l,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(2,3-dichlorophenyl)-l,3-thiazol-2-amine (52 mg, 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 45 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 2.32 (s; 3H), 3.16 (s, 3H), 3.42 (s, 3H), 3.83 (s, 2H), 7.46 (t, J= 7.8 Hz, 1H), 7.61 (s, 1H), 7.67 (d, J= 8.4 Hz, 1H), 7.74 (d, J= 7.8 Hz, 1H), 12.47 (br s, 1H); APCI-MS (m/z) 479.10 (M+H)+.
Example 56 N1-[4-(2,4-DichIorophenyl)-l,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(2,4-dichlorophenyl)-l,3-thiazol-2-amine (52 mg, 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 20 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6)δ 2.31 (s, 3H), 3.16 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.54 (dd, J= 2.1, 8.7 Hz, 1H), 7.64 (s, 1H), 7.73 (s, 1H), 7.87 (d, J= 8.4 Hz, 1H), 12.46 (br s, 1H); APCI-MS (m/z) 479.14 (M+H)+.
Example 57 N1-[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]-2-(1,3,6-trimethyl-2,4-dioxo-1,2,3,4 tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(2,4-difluorophenyl)-l,3-thiazol-2-amine (46 mg, 0.214 mmol) in the presence of sodium hydride (18 mg, 0.445 mmol) in dry toluene (10 ml) to give 46 mg of the product as a white solid: 1H NMR (300 MHz, DMSO-d6) 8 -2.32 (s, 3H), 3.16 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.22 (t, J= 8.4 Hz, 1H), 7.38 (t; J =8.7 Hz, 1H), 7.47 (s, 1H), 8.06 (q, J =6.9 Hz, 1H), 12.45 (br s, 1H); APCI-MS {m/z) 445.26 (M-H)
Example 58 N1 -{4-[4-Fluoro-3-(trifluoromethyl)phenyl]-l ,3-thiazol-2-yl} -2-( 1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-y])acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[4-fluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (89 mg, 0.339 mmol) in the presence of

sodium hydride (28 mg, 0.708 mmol) in dry toluene (10 m\) to give 70 mg of the product as an off-white solid; 'HNMR (300 MHz, DMSO-d6,) 6 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.61 (t, J= 9.6 Hz, 1H), 7.84 (s: 1H), 8.25-8.31 (m, 2H); 12.50 (br s, 1H); APCI-MS (m/z) 497.02 (M-H)
Example 59 Nl-{4-[3-Fluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-y|}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling intermediate 3 (80 mg. 0.285 mmol) with 4-[3-fluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (89 mg, 0.342 mmol) in the presence of sodium hydri.de (28 mg, 0.713 mmol) in dry toluene (10 ml) to give 61 mg of the product as an off-white solid: 'H NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.87-8.00 (m, 4H), 12.54 (br s, 1H); APC1-MS (m/z) 533.13 (M+H)+.
Example 60 N1-{4-[2-Fluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2~yl}-2-(l,3;6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[2-fluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (56 mg, 0.213 mmol) in the presence of sodium hydride (18 mg, 0.445 mmol) in dry toluene (10 ml) to give 20 mg of the product as an off-white solid; 1H NMR (300 MHz, DUSO-d6) 6 2.32 (s, 3H), 3.16 (s, 3H), 3.42 (s, 3H), 3.84 (s, 2H), 7.70-7.76 (m, 2H), 7.78-7.86 (m, 1H), 8.26 (t, J= 7.8 Hz, 1H), 12.55 (br s, 1H); APC1-MS (m/z) 497.07 (M+H)+.
Example 61 N1-{4-[2-Fluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling 'Intermediate 3 (100 mg, 0.357 mmol) with 4-[2-fluoro-3-(trifluoromethyi)phenyl]-l,3-thiazol-2-amine (112 mg, 0.465 mmol) in the presence of sodium hydride (35 mg, 0.875 mmol) in dry toluene (10 ml) to give 85 mg of the product as an off-white solid; lU NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.53 (t, J= 7.8 Hz, 1H), 7.68 (s, 1H), 7.72-7.80 (m, 1H), 8.33 (t, J = 7.5 Hz, 1H), 12.53 (br s, 1H): APCI-MS {m/z) 497.13 (M+H)+.
Example 62 N1-{4-[3-Fluoro-5-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2..4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling intermediate 3 (100 mg, 0.356 mmol) with 4-[3-fluoro-5-(lrifluoromethyl)phenyl]-l,3-thiazol-2-amine (112 mg, 0.429 mmol) in the presence of sodium hydride (35 mg, 0.891 mmol) in dry toluene (10 ml) to give 70 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) δ 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.65 (d, ./= 8.1 Hz, 1H), 7.99 (s, 1H), 8.07 (d, J= 9.9 Hz, 1H), 8.13 (s, 1H), 12.52 (br s, 1H); APCI-MS (m/z) 495.49 (M-H)".
Example 63 Arl-{4-[2-Fluoro~5-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-y])acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[2-fluoro-5-

(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (56 mg, 0.213 mmol) in the presence of sodium hydride (10 mg, 0.416 mmol) in dry toluene (10 ml) to give 17 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 8 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.55-7.65 (m, 1H), 7.69 (s, 1H), 7.76-7.82 (m, 1H), 8.39-8.45 (m, 1H), 12.55 (br s, 1H); APCI-MS (m/z) 497.06 (M+H)+.
Example 64 N1-{4-[4-Chloro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-y]}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrpfuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[4-chloro-3-(trifluoromethyl)phenyl]-],3-thiazol-2-amine (95 mg, 0.342 mmol) in the presence of sodium hydride (29 mg. 0.713 mmol) in dry toluene (10 ml) to give 76 mg of the product as an off-white solid; lH NMR (300 MHz, DMSO-d6) 6 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s,2H), 7.81 (d, 7=8.4 Hz, 1H), 7.92(s, 1H), 8.20 (d, J= 8.1 Hz, 1H), 8.35 (s, 1H), 12.52 (brs. 1H); APCI-MS (m/z) 513.10 (M+H)+.
Example 65 N-{4-[3-Chloro-5-trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1.2.3.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[3-chloro-5-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (60 mg, 0.2J4 mmol) in the presence of sodium hydride (18 mg. 0.445 mmol) in dry toluene (10 ml) to give 30 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.83 (s: 1H), 8.03 (s, 1H), 8.23 (s, 1H), 8.30 (s, 1H), 12.52 (br s, 1H); APCI-MS (m/z) 513.07 (M+H)+.
Example 66

Nl-{4-[3-Ch]oro-4-(trifluoromethyl)phenyl]-1,3-thiazo]-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg. 0.178 mmol) with 4-[3-chloro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (59 mg, 0.214 mmol) in the presence of sodium hydride (17 mg. 0.445 mmol) in dry toluene (10 ml) to give 50 mg of the product as a white solid; lH NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H),3.84(s, 2H), 7.93 (d, J = 8.1 Hz, 1H), 8.01 (s, 1H), 8.06 (d; J = 7.8 Hz, 1H), 8.23(s, 1H), 12.53 (brs, IH); APCI-MS (m/z) 513.13 (M)+.
Example 67 N1-{4-[3-Fluoro-4-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (100 mg, 0.356 mmol) with 4-[3-fluoro-4-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (119 mg, 0.428 mmol) in the presence of sodium hydride (35 mg, 0.890 mmol) in dry toluene (10 ml) to give 123 mg of the product as an;off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.60-7.69 (m, 1H), 7.80-7.90 (m, 2H), 7.95-8.02 (m, 1H), 12.49 (br s, 1H); APCI-MS (m/z) 513.26 (M+H)+.
Example 68 Nl-{4-[4-Fluoro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-y!}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[4-fluoro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (95 mg. 0.342 mmol) in the presence of sodium hydride (28 mg, 0.708 mmol) in dry toluene (10 ml) to give 70 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) δ 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.60 (t, J= 9.3 Hz, 1H); 7.79 (s, 1H), 8.00-8.06 (m, 2H), 12.48 (br s, 1H); APC1-MS (m/z) 513.15 (M+H)+.
Example 69 N1-{4-[4-Chloro-3-(trifluoromethoxy)phenyI]-l,3-thiazoI-2-yl}-2-(I,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg. 0.285 mmol) with 4-[4-chloro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (96 mg. 0.343 mmol) in the presence of sodium hydride (29 mg, 0.713 mmol) in dry toluene (10 ml) to give 62 mg of the product as an off-white solid; ]H NMR (300 MHz, DMSO-d6) 8 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.77 (d,J = 8.4 Hz, IH), 7.87 (s, 1H), 7.97 (d, J= 8.4 Hz, 1H), 8.03 (s, 1H), 12.50 (brs, IH); APCI-MS (m/z) 529.05 (M+H)+.
Example 70 Nl-{4-t3-Chloro-4-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (40 mg, 0.142 mmol) with 4-[3-chloro-4-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (50 mg, 0.169 mmol) in the presence of sodium hydride (14 mg, 0.333 mmol) in dry toluene (10 ml) to give 17 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 5 2.29 (s, 3H), 3.13 (s, 3H), 3.39 (s,

3H), 3.81 (s, 2H), 7.63 (d, J = 8.4 Hz, 1H), 7.83 (s, 1H), 7.97 (d, J= 8.4 Hz, 1H), 8.17 (s, 1H), 12.47 (br s, 1H); APCI-MS (m/z) 529.12 (M+H)+.
Example 71 N1-{4-[3-Chloro-5-(trifluoromethoxyphenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (40 mg, 0.142 mmol) with 4-[3-chloro-5-(trifluoromethoxy)phenyl]-l,3-thiazol-2-amine (50 mg, 0.169 mmol) in the presence of sodium hydride (14 mg, 0.333 mmol) in dry toluene (10 ml) to give 29 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.54 (s, 1H), 7.88 (s, 1H), 7.97 (s, IH), 8.05 (s, 1H), 12.50 (br s, 1H); APCI-MS (m/z) 529.11 (M+H)+.
Example 72 Nl-{4-[3-Chloro-4-(difluoromethoxy)phenyl]-1,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[3-chloro-4-(difluoromethoxy)phenyl]-l,3-thiazol-2-amine (59 mg, 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 25 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.09 (t J = 72.6 Hz), 7.45 (d, J = 8.1 Hz, 1H), 7.76 (s, 1H), 7.91-7.95 (d, J= 8.7 Hz,' 1H), 8.11 (s, 1H), 12.46 (br s, 1H); ESI-MS (m/z) 51 1.08 (M+H)+.
Example 73 Nl-{4-[3-Fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[3-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-1.3-thiazol-2-amine (62 mg, 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 75 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.82 (s, 2H), 4.89 (q, J = 9.0 Hz, 2H), 7.37 (t, J = 9.0 Hz, 1H), 7.63 (s, 1H), 7.70-7.76 (m, 1H), 7.80 (s: IH), 12.42 (brs, 1H); APCI-MS {m/z) 527.15 (M+H)+.
Example 74 Nl-{4-f(-Chloro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[3-chloro-4-(2,2,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-amine (66 mg. 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 21 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) δ 2.31 (s; 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.82 (s, 2H), 4.92 (q, J= 9.0 Hz, 2H), 7.35 (d, J= 8.7 Hz, 1H), 7.66 (s, 1H), 7.84-7.90 (m, 1H), 8.01 (s, 1H), 12.42 (br s, 1H); APCI-MS (m/z) 543.92 (M+H)+.
Example 75 N1-[4-(2,4,5-Trifluromethyl tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(2,4,5-Trifluorophenyl)-l,3-thiazol-

2-amine (49 mg, 0.212 mmol) in the presence of sodium hydride (10 mg, 0.416 mmol) in dry toluene (10 ml) to give 21 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.57 (s, 1H), 7.67-7.77 (s, 1H), 7.90-7.99 (m, 1H), 12.49 (br s, 1H); APCT-MS (m/z) 465.06 (M+H)+.
Example 76 Nl-[4-(3,4,5-Trifluorophenyl)-],3-thiazo]-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (40 mg, 0.142 mmol) with 4-(3,4,5-trifluorophenyl)-l,3-thiazol-2-amine (39 mg, 0.171 mmol) in the presence of sodium hydride (14 mg, 0.355 mmol) in dry toluene (.10 ml) to give 25 mg of the product as an off-white solid; ]H NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.76-7.85 (m, 3H), 12.48 (br s, 1H); APCI-MS (m/z) 465.09 (M+H)+.
Example 77 Nl-[4-(2,3,4-Trifluorophenyl)-l,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3,d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(2,3,4-trifluorophenyl)-l,3-thiazol-2-amine (49 mg, 0.214 mmol) in the presence of sodium hydride (18 mg, 0.445 mmol) in dry toluene (10 ml) to give 45 mg of the product as an off-white solid; !H NMR (300 MHz, DMSO-d6) 8 2.32 (s, 3H), 3.16 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.43-7.46 (m, 1H), 7.57 (s, 1H), 7.82-7.85 (m, 1H), 12.50 (brs, 1H); ESI-MS {m/z) 465.06 (M+H)+.
Example 78 Nl-[4-(3-Chloro-2,4-difluorophenyl)-1,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (40 mg, 0.142 mmol) with 4~(3-chloro-2,4-difluorophenyl)-l,3-thiazol-2-amine (42 mg, 0.170 mmol) in the presence of sodium hydride (14 mg, 0.333 mmol) in dry toluene (10 ml) to give 20 mg of the product as an off-white solid; H NMR (300 MHz, DMSO-d6) 5 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.45 (t, J = 8.1 Hz, 1H), 7.58 (s, 1H), 8.02 (q, J = 6.9 Hz, 1H), 12.50 (br s, 1H); APCI-MS (m/z) 481.09 (M+H)+.
Example 79 Nl -[4-(2,4-Dichloro-5-fluorophenyl)-l ,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(2,4-dichloro-5-fluorophenyI)-l,3-thiazol-2-amine (56 mg; 0.214 mmol) in the presence of sodium hydride (21 mg, 0.534 mmol) in dry toluene (10 ml) to give 24 mg of the product as an off-white solid; ]H NMR (300 MHz, DMSO-rfe) 5 2.27 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 7.77 (s, 1H), 7.85-7.96 (m, 2H), 12.50 (br s, 1H); APCI-MS (m/z) 497.06 (M+H)+.
Example 80 Nl-{4-(2,2-Dimethylpropoxy)-3,5-difluorophenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[4-(2,2-dimethylpropoxy)-3,5-difluorophenyl]-1.3-thiazol-2-amine (102 mg. 0.342 mmol) in the presence of sodium

hydride (28 mg, 0.713 mmol) in dry toluene (10 ml) to give 41 mg of the product as an off-white solid: 1H NMR (300 MHz, DMSO-d6) δ 1.01 (s, 9H), 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.80 (s, 2H), 3.82 (s, 2H), 7.64 (d, J= 9.3 Hz, 2H), 7.74 (s, 1H), 12.44 (br s, 1H); APCI-MS (m/z) 497.07 (M+H)+.
Example 81 Nl-[4-(3,5-Difluoro-4-isobutoxyphenyl)-l,3-thiazoI-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(3,5-difluoro-4-isobutoxyphenyl)-l,3-thiazol-2-amine (60 mg. 0.214 mmol) in the presence of sodium hydride (28 mg, 0.445 mmol) in dry toluene (10 ml) to give 38 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) 8 0.98 (d, J= 6.6 Hz, 6H), 1.92-2.03 (m, 1H), 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.82 (s, 2H), 3.91 (d, J= 6.3 Hz, 2H), 7.63 (d, J= 9.3 Hz, 2H), 7.73 (s, 1H); 12.44 (br s, 1H); APCI-MS (m/z) 519.19 (M+H)+.
Example 82 N1-[4-(3,5-Dichloro-4-isobutoxyphenyl)-l,3-thiazo!-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl]acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-(3,5-dichloro-4-isobutoxyphenyl)-l,3-thiazol-2-amine (68 mg, 0.214 mmol) in the presence of sodium hydride (18 mg, 0.445 mmol) in dry toluene (10 ml) to give 35 mg of the product as an off-white solid; ]H NMR (300 MHz, DMSO-d6) δ 1.05 (d, J= 6.9 Hz, 6H), 2.27 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.78-3.83 (m, 4H), 7.82 (s, 1H), 8.01 (s, 2H), 12.45 (br s, IH); ESI-MS (m/z) 551.10 (M+H)+
Example 83

N1 - {4-[2,4-Diflu6ro-3-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl }-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[2,4-difluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (96 mg, 0.343 mmol) in the presence of sodium hydride (29 mg, 0.713 mmol) in dry toluene (10 ml) to give 85 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s, 2H), 7.53 (t, J =93 Hz, 1H), 7.64 (s, 1H), 8.33-8.35 (m, 1H), 12.53 (br s, 1H); APCI-MS (m/z) 515.24 (M+H)+.
Example 84 Nl-{4-[3,5-Difluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The tiuc compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[3,5-difluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-amine (95 mg, 0.342 mmol) in the presence of sodium hydride (28.5 mg, 0.712 mmol) in dry toluene (15 ml) to give 86 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.84 (s; 2H), 7.84 (s; 1H), 7.88 (s, 1H), 8.08 (s, 1H), 12.56 (br s, 1H); APCI-MS (m/z) 515.04 (M+H)+.
Example 85 N1-{4-[3,5-Difluoro-4-(difluoromethoxy)phenyl]-l;3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[3,5-difluoro-4-(difluoromethoxy)phenyl]-1.3-thiazo]-2-amine (59 mg, 0.212 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 30 mg of the product as an off-white solid; 'H NMR (300 MHz, DMSO-d6) δ 2.31 (s, 3H), 3.15 (s; 3H), 3.41 (s, 3H), 3.83 (s,,2H), 7.28 (t,J= 72.3 Hz, 1H), 7.79 (d,7= 9.9 Hz, 2H), 7.88 (s, 1H), 12.50 (brs, 1H); APCl-MS(m/z) 513.11 (M+H)+.
Using the similar procedure as described in method A or B, additional examples of furopyrimindiedione acetamides with multiple fluorine substitutions (as depicted in Table 3) can be prepared by coupling 2,4-dioxofuropyrimidinyl acetic acid or their ester with an appropriate fluorinated 2-amino-4-arylthiazole selected from Table 2. Table 3: Additional examples of fluorinated furopyrimindiedione acetamide derivatives





Example 86 Nl-{4-[3,5-Dichloro-4-(difluoromethoxy)phenyl]-1,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.170 mmol) with 4-[3,5-dichloro-4-(difluoromethoxy)phenyl]-l,3-thiazol-2-amine (62 mg, 0.200 mmol) in the presence of sodium hydride (16 mg, 0.420 mmol) in dry toluene (10 ml) to give 60 mg of the product as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 231 (s, 3H), 3.15 (s. 3H), 3.4] (s, 3H), 3.83-(s, 2H), 7.20 (t, J =72.0 Hz, 1H), 7.94 (s, 1H), 8.12 (s, 2H), 12.49 (br s, }H): APCI-MS (m/z) 545.12 (M+H)+.

Example 87 N1-{4-[3,5-Difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetarnide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (80 mg, 0.285 mmol) with 4-[3,5-difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-amine (106 mg, 0.343 mmol) in the presence of sodium hydride (29 mg, 0.713 mmol) in dry toluene (10 ml) to give 64 mg of the product as an off-white solid: 'H NMR (300 MHz, DMSO-d6) δ 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 4.87 (q, J= 8.7 Hz, 2H), 7.69 (s, IH), 7.72 (s, 1H), 7.80 (s, 1H), 12.47 (br s, 1H); APCI-MS (m/z) 545.07 (M+H)+.
Example 88 N1-{4-[3,5-Dichloro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (42 mg, 0.150 mmol) with 4-[3,5-dichloro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-amine (62 mg, 0.180 mmol) in the presence of sodium hydride (14 mg, 0.370 mmol) in dry toluene (10 ml) to give 17 mg of the product as an off-white solid: 'H NMR (300 MHz, DMSO-d6) 6 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 4.76 (q, J = 8.7 Hz, 2H), 7.87 (s, 1H), 8.05 (s, 2H), 12.47 (br s, 1H); APCr-MS (m/z) 571 AS (M+H)+.
Example 89 N1-{4-[4-(Cyclopropylmethoxy)-3,5-difluorophenyl]-l,3-thiazol-2-y]]-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3,d]pyrimidin-5-yl)acetamide


The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[4-(cyclopropylmethoxy)-3,5-difluorophenyl]-l,3-thiazol-2-amine (60 mg. 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 19 mg of the product as a white solid; lH NMR (300 MHz, DMSO-d6;) 5 0.23-0.30 (m, 2H), 0.50-0.56 (m, 2H), 1.18-1.24 (m, 1H), 2.31 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 3.83 (s, 2H), 3.97 (d, ./= 7.2 Hz, 2H),7.62,(s, 1H), 7.74(s, 1H), 12.45 (br s, 1H); APC1-MS (m/z) 517.14 (M+H)+.
Example 90 Nl-{4-[4-Fluoro-3-(trifluoromethyl)phenyl]-5-methyl-l,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 3 (50 mg, 0.178 mmol) with 4-[4-fluoro-3-(trifluoromethyl)phenyl]-5-methyl-l,3-thiazol-2-amine (59 mg, 0.214 mmol) in the presence of sodium hydride (17 mg, 0.445 mmol) in dry toluene (10 ml) to give 26 mg of the product as a white solid; lH NMR (300 MHz, CDC13) δ 2.41 (s, 3H); 2.47 (s, 3H), 3.47 (s, 3H). 3.54 (s, 3H), 3.70 (s, 2H), 7.18-7.26 (m, 1H), 7.76-7.83 (m, 1H), 7.85-7.90 (m, 1H), 11.42 (br s, 1H); APCI-MS {m/z) 511.08 (M+H)+.
Example 91 Nl-[5-(4-Bromophenyl)-l,3,4-thiadiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide

The title compound was prepared according to the general procedure (Method B) by coupling Intermediate 4 (45 mg, 0.178 mmol) with 5-(4-bromophenyl)-l,3,4-thiadiazol-2-

amine (45 mg, 0.178 mmol) in the presence of EDCI hydrochloride (40 mg, 0.214 mmol), HOBt (7 mg, 0.053 mmol) and DMAP (2 mg, 0.017 mmol) in 1,2-dichloroethane (5 ml) to give 13 mg of the product as a white solid; ]H NMR (300 MHz, DMSO-d6) 5 2.32 (s, 3H), 3.15 (s, 3H), 3.41 (s, 3H), 4.03 (s, 2H), 7.66-7.75 (m, 2H), 7.84-7.90 (m, 2H), 12.89 (br s, 1H); APCI-MS (m/z) 490.09 (M)+.
Pharmacological activity
The illustrative examples of the present invention are screened for TRPAI activity according to a modified procedure described in (a) Toth, A. et al. Life Sciences, 2003, 73, 487-498. (b) McNamara C, R. el al, Proc. Natl. Acad Sci. U.S.A., 2007, 104, 13525-13530. The screening of the compounds can be carried out by other methods and procedures known to persons skilled in the art.
Screening for TRPAI antagonist using the 45Calcium uptake assay:
The inhibition of TRPA1 receptor activation was measured as inhibition of allyl isothiocyanate (AITC) induced cellular uptake of radioactive calcium.
Test compounds were dissolved in 100% DMSO to prepare 10 mM stock and then diluted using plain medium with 0.1% BSA and 1.8 mM CaCl2 to get the desired concentration. The final concentration of DMSO in the reaction was 0.5% (v/v). Human TRPA1 expressing CHO cells were grown in F-12 DMEM medium with 10% FBS, 1% penicillin-streptomycin solution, and 400 μg / ml of G-4I8. Rat TRPAI expressing CHO cells were grown in F-12 DMEM medium with 10% FBS, 1% penicillin-streptomycin solution, and 400 μg / ml of Zeocin. Cells were seeded 24 h prior to the assay in 96 well plates so as to get ~ 50,000 cells per well on the day of experiment. Cells were treated with the test compounds for 10 minutes followed by the addition of AITC at a final concentration of 30 μM (for human TRPAI) and / or 10 μM (for rat TRPAI) and 5 μCi/ml 45Ca+2 for 3 minutes. Cells were washed and lysed using a buffer containing 1% Triton X-100, 0.1 % deoxycholate and 0.1% SDS. Radioactivity in the lysate was measured in- a Packard TopCount after addition of liquid scintillant. (Toth et al, Life Sciences (2003) 73, 487-498; McNamara CR et al, Proceedings of the National Academy of Sciences, (2007) 104. 13525-13530).
Concentration response curves were plotted as a % of maximal response obtained in the absence of test antagonist. IC50 values can be calculated from concentration response curve by nonlinear regression analysis using GraphPad PRISM software.

The compounds prepared were tested using the above assay procedure and the results obtained are given in Table 4. Percentage inhibition at concentrations of 1.0 uM and 10.0 μM are given in the table along with IC50 (nM) details for selected examples. The IC50 (nM) values of the compounds are set forth in Table 4 wherein "A" refers to an IC50 value of less than 50 nM; "B" refers to IC50 value in range of 50.01 to 100.0 nM and "C" refers to IC50 value of more than 100.0 nM
Table 4: In-vitro screening results of compounds of invention:

human TRPA1 rat TRPA1
Examples Percentage inhibition IC50 value
(nM) Percentage inhibition IC50 value (nM)

at 1.0 nM at 10.0 uM
at 1.0 uM at 10.0 μM

Example 1 ~ - C 96.65 100.00 -
Example 6 100 99.58 A ~ - ~
Example 7 98.76 99.75 A -- „ ~
Example 8 . 93.15 98.82 A 100.00 100.00 A
Example 9 99.33 100 A - ~
Example 10 98.54 97.71 A 97.55 100.00 B
1 Example 13 98.53 99.36 A - ~ C
Example 14 ■. 99.39 99.74 A 100.00 100.00 A
Example 15 99.9 99.85 A 100.00 98.95 A
Example 16 98.51 99.17 A 99.96 98.63 A
Example 17 ' 99.94 99.97 A 97.71 99.83 B
Example 18 99.9 100 A 99.90 94.08 B
Example 19 99.9 100 A 98.88 98.22 B
Example 20 98.48 97.55 A 96.80 99.79 A
Example 21 , 99.85 99.8 A 98.88 99.90 A
Example 22 99.26 98.47 A 100.00 100.00 ~
Example 23' 96.35 99.02 A 92.57 95.54 C
Example 24 97.4 99.85 A 100.00 99.62 C
Example 25 99.33 99.83 A ~ - ~

Example 26 97.57 99.31 A 98.59 99.87 —
Example 27 97.14 99.2 C 93.13 100.00 -
Example 28 96.71 99.31 C 98.46 100.00 -
Example 30 97.43 100 A 97.09 100.00 c
Example 31 98.32 99.82 A 96.75 100.00 B
Example 32 99.8 99.54 A 85.16 100.00 A
Example 33 97.87 98.1 A - — -
Example 34 97.05 99.72 A 91.01 99.27 B
Example 35 99.85 98.38 A - — A
Example 36 99.73 99.6 A 100.00 100.00 B
Example 37 99.9 99.74 A 100.00 100.00 B
Example 38 99.79 99.9 A 67.01 100.00 C
Example 39 94.18 98.68 A - — C
Example 40 93.2 99.17 A 99.20 99.57 A
Example 41 99.56 100 A 99.53 100.00 A
Example 42 96.13 99.9 A ~ — A
Example 43 99.23 99.7 A 89.21 100.00 B
Example 44 100 99.51 A 71.04 99.25 A
Example 45 90.67 98.14 A — — ~
Example 46 99.85 100 A 96.12 99.54 B
Example 47 99.18 99.8 A 86.03 100.00 A
Example 48 96.59 95.12 A 99.58 99.16 A
Example 49 95.58 98.26 •A 86.62 97.70 A
Example 50 99.64 98.35 - 99.87 100 ~
Example 51 99.77 99.96 — 100 100 —
Example 52 99.08 99.15 - 100 100 ~
Example 53 99.73 97.28 -- 100 100 -

Example 54 — — A -- — B
Example 55 95.83 99.03 - 97.66 100 -
Example 58 - - A - — A
Example 59 - - A — — B
Example 60 - - A 99.32 99.65 B
Example 61 - - A - ~ A .
Example 62 - - A - ~ A
Example 63 - - B 97.63 99.80 ~
Example 64 - - A -- - A
Example 65 — ~ A 99.79 99.80 B
Example 66 99.38 99.85 99.85 98.50 -
Example 61 - - A -- — A
Example 68 - - A -- - A
Example 69 - ~ A - ~ A
Example 70 - - A — ~ A
Example 71 - - A ~ — B
Example 72 - - A 100 100 C
Example 73 - ~ A 100 100 —
Example 74 - ~ A 100 100 A
Example 77 - - A 99.15 98.55 —
Example 78 - ~ A 94.5 94.8 —
Example 80 - - A — — A
Example 81 - - A 100 99.25 B
Example 82 ~ - A 99.96 100 A
Example 83 - - A — — A
Example 84 ~ - A — — A
Example 85 - A 100 100 -

Example 86 — ~ A 99.(2 95.41 A
Example 87 — — A — — A
Example 88 — ~ A 98.26 100 «
Example 89 __ ~ A - 98.81 B
Example 90 - - A 97.98 99.52 -

WE CLAIM:
I. A compound of the formula (I)

or a pharmaceutically acceptable salt thereof, wherein,
R1 arid R2, which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alky], alkenyl. alkynyl, cycloalkyl, cycloalkylalkyl, arylalkyl, (CRxRy)n, C(0)RxJ C(0)ORx, C(0)NRxRy (CH2)nNRxRy, (CH2)nCHRxRy, NRx(CRxRy)nCONRxRy, (CH2)nNRxRy and (CH2)nNHC(0)Rx;
R is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl and cycloalkenyl;
Zj and Z2 are independently oxygen or CRa; with a proviso that one of Z, or Z2 is always oxygen and other is CRa;
L is a linker selected from -(CRxRy)n- -0-(CRxRy)„-. -C(O)-, -NRX-, -S(0)mNRx-, -NRx(CRxRy)n- and -S(0)mNRx(CRxRy)n;
at each occurrence. Ra is selected from hydrogen, cyano, substituted or unsubstituted alkyl. alkenyl. alkynyl, cycloalkyl, cycloalkylalkyl, aryl. arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring, heterocyclylalkyl, ORx, (CRxRy)nORx, C(0)Rx, C(o!)ORx; C(0)NRxRy, S(0)mNRxRy, NRxRy, NRx(CRxRy)nOR\ (CH2)nNRxRy, (CH2)nCHRxRy, NRx(CRxRy)nC(0)NRxRy, (CH2)nNHC(0)Rx, (CH2)nNH(CH2)nS02Rx, (CH2)nNHS02R\ SRx and ORx;
U is selected from -(CRxRy)n-i substituted or unsubstituted aryl, substituted or unsubstituted five membered heterocycles selected from the group consisting of thiazole, isothiazole, oxazole, isoxazole, thiadiazote, oxadiazole, pyrazole, imidazole, furan, thiophene, pyrrole, 1,2,3-triazole and 1, 2, 4-triazole, or substituted or unsubstituted six membered heterocycle selected from the group consisting of pyrimidine, pyridine and pyridazine;

V is selected from hydrogen, cyano. nitro, -NRxRy, halogen, hydroxy I, substituted or unsubstituted alkyl, alkenyl, alkynyl. cycloalkyl, cycloalkylalkyl, cycloalkenyl, haloalkyl, haloalkoxy, cycloalkylalkoxy, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylalkyl, -C(0)ORx, -ORx, -C(0)NRxRy. -C(0)Rx and -S02NRxRy; or
alternatively U and V together may form an optionally substituted 3 to 7 membered saturated or unsaturated cyclic ring thai may optionally include one or more heteroatoms selected from 0, S and N;
at each occurrence, RlX and Ry are independently selected from hydrogen, hydroxy!, halogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylalkyl and
at each occurrence, 'm' and V are independently selected from 0 to 2. both inclusive.
2. The compound according to claim 1, wherein Z1 is oxygen and Z2 is CRa.
3. The compound according to claim 1, wherein Z2 is oxygen and Z1is CRa.
4. The compound according to claim 2 or 3, wherein Ra is hydrogen.
5. The compound according to claim 2 or 3, wherein Ra is methyl.
6. The compound according to any of claims 1 to 5, wherein L is CH2.
7. The compound according to any of claims I to 6, wherein R1 and R2 are (C]-C4)alkyl.
8. The compound according to claim 7, wherein (C1-C4)alkyl is methyl.
9. The compound according to any of claims 1 to 8, wherein R3 is hydrogen.
10. The compound according to any of claims 1 to 9, wherein U is heteroaryl.
11. The compound according to claim 10, wherein heteroaryl is thiazole, imidazole, isoxazole, pyrazole, thiadiazole or pyrimidine.
12. The compound according to any of claims 1 to 11, wherein V is substituted or unsubstituted aryl.
13. The compound according to claim 12, wherein aryl is phenyl.
14. The compound of claim 1 having the formula (la):


15. The compound according to claim 14, wherein R1 and R2are (C1-C4)alkyl.
16. The compound according to claim 15, wherein (C1-C4)alkyl is methyl.
17. The compound according to any of claims 14 to 16, wherein Ra is hydrogen or (C1-C4)alkyl.
18. The compound according to any of claims 14 to 17, wherein U is heteroaryl.
19. The compound according to claim 18, wherein heteroaryl is thiazole, imidazole, isoxazole, pyrazole, thiadiazole or pyrimidine.
20. The compound according to any of claims 14 to 19, wherein V is substituted or unsubstituted aryl.
21. The compound according to claim 20, wherein aryl is phenyl.
22. A compound having the structure:

(1c) or a pharmaceutically acceptable salt thereof, wherein,
R1, R and Ra, which may be the same or different, are each independently hydrogen or (C1-C4)alkyl; and
R4, R5; R6, R7, R8 and R9, which may be same or different, are each independently selected from the group comprising of hydrogen, halogen, cyano, hydroxyl, nitro, amino, substituted or unsubstituted alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl,

cycloalkylalkyl, cycloalkenyl, cycloalkylalkoxy, aryl, arylalkyl, biaryl, heteroaryl, heteroarylalkyl, heterocyclic ring and heterocyclylalkyl.
23. The compound according to claim 22 wherein Ra is hydrogen
24. The compound according to claim 22 wherein Ra is (C1-C4)alkyl.
25. The compound according to any of claims 22 to 2 wherein R1 and R2 are (C1-C4)alkyl.
26. The compound according to claim 24 or 25, where'" (C1-C4)alkyl is methyl.
27. The compound according to any of claims 22 to 20> wherein R4 and Rs are independently selected from the group consisting of hydrogen, fluoro, trifluoromethyl or trifluoromethoxy.
28. The compound according to any of claims 22 to 27 wherein R6 and R7 are independently selected from the group consisting of hydrogen, fluoro, trifluoromethyl or trifluoromethoxy.

29. The compound according to any of claims 22 to 28 wherein R8 is hydrogen.
30. The compound according to any of claims 22 to 29 wherein R9 is hydrogen.
31. The compound according to any of claims 22 to 29' wherein R9 is methyl.
32. The compound selected from: N1-.[4-(4-Trifluoromethylphenoxy)phenyl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-
tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-[2-(2,4-Dichlorophenyl)ethyl]-2-(l,3-dimethyl-2,4,-dioxo-1,2,3,4 tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N1-[4-(Trifluoromethyl)-1,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4
tetrahydrofuro[2,3-d]pyrirnidin-5-yl)acetamide;
N-(4,6-Difluoro-l,3-benzothiazol-2-y])-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-
tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-[4-(4-lsobutylphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4 tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[4-(Trif1uoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(13-dimethyl-2,4-dioxo-
l,2,3.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[3-(Trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(1,3-dimethyl-2,4-dioxo-
1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;

N.[4-(4-Trifluororrnethoxyphenyl)-l,3-thiazol-2-yl]-2-(1,3-dimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2.3-(/|pyrimidin-5-yl)acetamide;
N-[4-(3-Trifluorormethoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2.4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-[4-(3-Bromo-4-fluorophenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide;
N-[4-(3,4-Difluorophenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-[4:-(2,4-DifluorophenyI)-1,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-[4-(3,4-Dichloropheny])-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3;4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[3-Fluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[4-Fluoro-3-(trifluoromethyl)phenyl]-];3-thiazol-2-yl}-2-(l,3-dimethy]-2,4-dioxo-l,2.3,4-tetrahydrofuro[2.3-d]pyrimidin-5-yl)acetamide;
N-{4-[4-Fluoro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(1,3-dimethyl-2.4-dioxo-l,2.3,4-tetrahydrofuro[2.3-6(]pyrimidin-5-yI)acetamide;
N -{4-[3-Fluoro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl} -2-( 1,3-dimethyl-2,4-dioxo~l,2,3,4-tetrahydrofuro[2,3-fl]pyrimidin-5-yl) acetamide;
N-{4-[4-Ch[oro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(F3-dimethyl-2,4-dioxo-].2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[4-Chloro-3-(trifluoromethoxy)phenyl]-1,3-thiazoi-2-yl]-2-(l,3-dimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d](pyrimidin-5-yl)acetamide;
Nl-{4-[2-F]uoro-3-(trifluoromethyl)phenyl]-1,3-thiazo]-2-yl}-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[3-Fluoro-5-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[2-Ftuoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-],2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-[4-(3-Fluoro-4-difluoromethoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
A'l-[4-(3-Chloro-4-difluoromethoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide; and

N -[4-(3-Bromo-4-difluoromethoxyphenyl)-1,3-thiazol-2-yl]-2-( 1,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2-3-d]pyrimidin-5-yl)acetamide; or a pharmaceutically acceptable salt thereof, 33. The compound selected from:
Nl-{4-[4-(2,2-Dimethylpropoxy)-3-fluorophenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3:4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
NI-{4-[3-Chloro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl]acetamide;
N-{4-[3-Bromo-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-[4-(3-Bromo-4-isobutoxyphenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-Fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[3-Chloro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazoI-2-yl}2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-Bromo-4-(2,2,2-trifluoroethoxy)phenyl]-],3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuran[2,3-d]pyrimidin-5-yl)acetamide;
N1-[4-(2,4,5,-Trifluorophenyl)-l,3-thiazol-2-yl]-2-(l,3-dimethyI-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-[4-(2,3,4-Trichlorophenyl)-1,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[2,4-Difluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d]pynmidin-5-yI)acetamide;
Nl-{4-[3,5-Difluoro-4-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3,5-Difluoro-4-(difluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3.4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3,5-Dichloro-4-(difluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-y[)acetamide;
Nl-{4_[4-(Cyclopropylmethoxy)-3,5-difluorophenyl]-1,3-thiazol-2-yl]-2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N1-{4-(3:5-Difluoro-4-isobutoxyphenyl)-l,3-thiazol-2-yl}2-(l,3-dimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;

N1-[4-(3,5-Dichloro-4-isobutoxyphenyl)-l,3-thiazol-2-yl]-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N1-{4-[3,5-Difluoro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thiazol-2-yI}2-(I,3-dimethyI-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3,5-Dichloro-4-(2,2-dimethy]propoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-y])acetamide;
N1-{4-[3-Chloro-5-fluoro-4-(2,2-dimethylpropoxy)phenyl]-l,3-thia2ol-2-yl}-2-(l,3-dimethyl-2.4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[3,5-Difluoro-4-(3-methylbutoxy)phenyl-1,3-thiazol-2-yl}-2-(1,3-dimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pynmidin-5-yl)acetamide;
N -{4-[3,5-Di fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-yl} -2-( 1,3-dimethyl-2.4-dioxo-l.2,3,4-tetrahydrofuro[2,3-t/]pyrimidin-5-yl)acetamide;
N-{4-[3,5-Dich]oro-4-(2s2,2-trifluoroethoxy)phenyl]-l)3-thiazo]-2-yl}2-(l,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuran[2,3-d]pyrimidin-5-yl)acetamide
N-{4-[3-Chloro-5-fluoro-4-(2,2,2-trifluoroethoxy)phenyl]-l,3-thiazol-2-yl}-2-(1,3-dimethyl-2,4-dioxo-l,23,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide; and
N1-{4-[3,5-Difluoro-4-(3,3,3-trifluoropropoxy)phenyl]-l,3-thiazol-2-yl}-2-(1,3-dimethyl-2,4-dioxo-],2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
or a pharmaceutically acceptable salt thereof,
34. The compound selected from:
Nl-{4-[4-(Trifluoromethyl)phenyI]-1,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-(Trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-(Trifluoromethoxy)phenyl]-1,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[4-(Trifluoromethoxy)phenyl]-1,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuran[2,3-d]-pyrimidin-5-yl)acetamide;
N-[4-(3,4-Dichlorophenyl)-l,3-thiazol-2-yl]-2-(l,3,6-trimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2,3-^Jpyrimidin-5-yl)acetamide;
N -[4-(2,3-Dichlorophenyl)-1,3-thiazol-2-yl]-2-( 1 ,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2-3-d]pyrimidin-5-yl)acetamide;

V -[4-(2,4-Dichlorophenyl)-l ,3-thiazol-2-yI]-2-(l,3;6-trimethyl-2,4-dioxo-I,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yI)acetamide;
N -[4-(2,4-Difluorophenyl)-1,3-thiazol-2-yl]-2-( 1,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-y])acetamide;
Nl-{4-[4-Fluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l?3,6-trimethy!-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-Fluoro-4-(trifluoromethyl)phenyl]-],3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[2-Fluoro-4-(trifluoromethyl)phenyl]-1)3-thiazol-2-yl}-2-(l,3;6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[2-Fluoro-3-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2.3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-Fluoro-5-(trifluoromethyl)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[2-Fluoro-5-(trifluoromethy])phenyl]-1.3-thiazol-2-yl}-2-(],3,6-trimethyl-2,4-dioxo-l,2,3.4-tetrahydrofuro[2,3-£/]pyrimidin-5-yl)acetamide;
N1-{4-[4-Chloro-3-(trifluoromethyl)phenyl]-],3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3;4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-Chloro-5-(trifluoromethyl)phenyl]-],3-thiazol-2-y]}-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
Nl-{4-[3-Chloro-4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl}-2-(1,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[3-F!uoro-4-(trifluoromethoxy)phenyl]-1,3-thiazol-2-yl}-2-(I,3,6-trimethyl-2,4-dioxo-],2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
NI-{4-[4-FIuoro-3-(trifluoromethoxy)phenyl]-l;3-thiazoI-2-yl}-2-(I:3,6-trimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide;
N-{4-[4-Chloro-3-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]-pyrimidin-5-yl)acetamide;
Nl-{4-[3-Chloro-4-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-(l,3,6-trimethy]-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide; and
N -{4-[3-Chloro-5-(trifluoromethoxyphenyl]-1,3-thiazol-2-yl} -2-( ] ,3,6-trimethy l-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide; or a pharmaceutically acceptable salt thereof,

35. The compound selected from:
Nl-{4-[3-Chloro-4-(difluoromethoxy)phenyl]-i,3-thiazol-2-y]}-2-(l,3,6-trimethyl^^-dioxo-l^.S.^-tetrahydrofuro^^-^lpyrimidin-S-y^acetamide;
A^l-{4-[3-Fluoro-4~(232,2-trifluoroethoxy)phenyl]-1,3-thiazol-2-yl}-2-(l,3;6-trimethyl-2;4-dioxo-l,2,3-4-tetrahydrofuro[2,3-£/|pyrimidin-5-yl)acetamide:
iVl-{4-[3-Chloro-4-(2>2,2-trifluoroethoxy)pheny]]-l,3-thiazol-2-yl}-2-(l,3,6-trimethyl^^-dioxo-l^J^-tetrahydrofuroP^-^pyrimidin-S-ylJacetamide;
M-{4-(2;4,5-Trifluorophenyl)-l,3-thJazol-2-y]]-2-(J,3,6-trimethyl-2;4-dioxo-l;253,4-tetrahydrofuro[2,3-t/]pyrimidin-5-yl)acetamide;
N] -[4-(3!4,5-Trifluorophenyl)-1:3-thiazol-2-yl]-2-( 1,3,6-trimethyl-2,4-dioxo-1.2,3,4-tetrahydrofuro[2,3-^pyrimidin-5-yl)acetamide:
Nl-[4-(2!3;4-Trifluorophenyl)-l,3-thiazoN2-yl]-2-(1,3,6-trimethy]-2,4-dioxo-l,2,3,4-tetrahydrofuro[2.3-o]pyrimidin-5-yl)acetamide;
A^l-^^-Chloro^^-difluorophenyO-lJ-thiazoI^-yn^-fl^^-trimethyl^^-dioxo-l^J^-tetrahydrofuro^^-^pyrimidin-S-yOacetamide;
M-[4-(2,4-Dich]oro-5-fluorophenyl)-l,3-thiazo]-2-y]]-2-(l,3,6-trimethyl-2,4-dioxo-l!2,3,4-tetrahydrofuro[2,3-^]pyrimidin-5-y])acetamide;
A^l-{4-(2,2-Dimethylpropoxy)-3,5-difluoropheny]]-l!3-thiazol-2-y]}-2-(l:3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-^]pynmidin-5-yI)acetamide;
A^l-[4-(3;5-Difluoro-4-isobutoxyphenyl)-];3-thiazol-2-y[J-2-(lJ3?6-trimethyl-2f4-dioxo-1.2,3,4-tetrahydrofuro[2,3-i/]pyrimidin-5-yl)acetamide;
N\ -[4-(3;5-Dichloro-4-isobutoxyphenyl)-1,3-thiazol-2-yl]-2-(l ,3,6-trimethyl-2,4-dioxo-l32,3.4-tetrahydrofuro[2,3-^pyrimidin-5-yl)acetamide;
Nl-{4-[234-Difluoro-3-(trifluoromethyl)phenyl]-l,3-thiazo]-2-yl}-2-( 1,3,6-trimethyl-2,4-dioxo-J,2.3,4-tetrahydrofuro[2,3-^/(pynmidin-5-y!)acetamide;
Ari-{4-[3,5-Difluoro-4-(trifluoromethyl)phenyl]-ls3-thiazoI-2-yl}-2-(l,3,6-trimethyl-2,4-dioxo-1,2,3,4-tetrahydrofuro[2,3-rf|pyrimidin-5-yl)acetamide;
A^l-{4-[3!5-Difluoro-4-(difluoromethoxy)phenyl]-1)3-thiazol-2-y]}-2-(l,3;6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2.3-f/]pyrimidin-5-yl)acetamide;
Arl-{4-[3,5-Dichloro-4-(difluoromethoxy)phenyl]-l,3-thiazof-2-yl}-2-(]!3,6-trimethyl-2,4-dioxo-l32,354-tetrahydrofuro[2,3-^]pyrimidin-5-yl)acetamide:
M-{4-[3,5-Difluoro-4-(2,2,2-trifluoroethoxy)phenyl]-I,3-thiazol-2-yl}-2-(l)3s6-trimethyl-2,4-dioxo-l,253,4-tetrahydrofuro[2.3-(/]pyrimidin-5-yl)acetamide;

7V]-{4-[355-Dichloro-4-(2,2,2-trifluoroethoxy)phenyl]-K3-thiazol-2-y]}-2-(],3,6-trimethyl^^-dioxo-l^^^-tetrahydrofuro^^-^pyrimidin-S-yOacetamide;
JVl-{4-[4-(Cyclopropylmethoxy)-3,5-difluorophenyl]-l)3-thiazol-2-yl]-2-(l,3,6-trimethyl-2.4-dioxo-l,2,3,4-tetrahydrofuro[2,3-£/]pyrimidin-5-yl)acetamide;
Afl-{4-[4-F]uoro-3-(trifluoromethyl)pheny]]-5-methyl-],3-thiazoi-2-yl}-2-(l,3,6-trimethy]-2J4-dioxo-],2,3s44etrahydrofuro[2J3-^pyrimidin-5-yl)acetamide; and
M-tS^-BromophenyO-I^^-thiadiazol-S-yll^-Cl^.e-trimethyl^^-dioxo-l,2.3,4-tetrahydrofuro[2,3-t/]pyrimidin-5-yl)acetamide:
or a pharmaceutically acceptable salt thereof.
36. The compound having the structures:

37. Tte tompOTHMl NH4-^-CMOYO-4-^
(],3.6-trimethyl-234-dioxo-I,2,3,4-tetrahydrofuro[2?3-t/|pyrimidin-5-yl)acetamide.
38. The compound N\-{4-[3-chloro-4-(trifluoromethoxy)phenyl]-l,3-thiazol-2-yl}-2-
(],3,6-trimethyl-2;4-dioxo-l,2J3!4-tetrahydrofuro[2,3-t/]pyrimidin-5-y])acetamide)or
pharmaceutically acceptable salt thereof.
39. The compound Nl -[4-(233-difluoro-4-trifluoromethyIphenyl)-l,3-thiazol-2-yl]-2-
(l,3,6-trimethyl-2,4-dioxo-l,2,3,4-tetrahydrofuro[2,3-d]pyrimidin-5-yl)acetamide, or
pharmaceutically acceptable salt thereof.
40. A pharmaceutical composition comprising one or more compounds selected from
the compounds of any one of claims 1 to 38, and one or more pharmaceutically
acceptable excipients, carriers, diluents or mixture thereof.

Documents:

916-mumnp-2011-abstract.doc

916-mumnp-2011-abstract.pdf

916-mumnp-2011-claims.doc

916-mumnp-2011-claims.pdf

916-MUMNP-2011-CORRESPONDENCE(12-2-2014).pdf

916-MUMNP-2011-CORRESPONDENCE(12-6-2013).pdf

916-MUMNP-2011-CORRESPONDENCE(14-8-2013).pdf

916-MUMNP-2011-CORRESPONDENCE(20-06-2014).pdf

916-MUMNP-2011-CORRESPONDENCE(6-5-2011)-.pdf

916-MUMNP-2011-CORRESPONDENCE(6-5-2011).pdf

916-MUMNP-2011-Correspondence-191214.pdf

916-mumnp-2011-correspondence.pdf

916-mumnp-2011-description(complete).pdf

916-MUMNP-2011-EP DOCUMENT(28-12-2012).pdf

916-mumnp-2011-form 1.pdf

916-MUMNP-2011-FORM 13(6-5-2011).pdf

916-MUMNP-2011-FORM 18(6-5-2011).pdf

916-mumnp-2011-form 2(title page).pdf

916-mumnp-2011-form 2.doc

916-mumnp-2011-form 2.pdf

916-MUMNP-2011-FORM 3(12-2-2014).pdf

916-MUMNP-2011-FORM 3(12-6-2013).pdf

916-MUMNP-2011-FORM 3(14-8-2013).pdf

916-MUMNP-2011-FORM 3(19-4-2012).pdf

916-MUMNP-2011-FORM 3(20-06-2014).pdf

916-MUMNP-2011-FORM 3(20-12-2011).pdf

916-MUMNP-2011-FORM 3(28-12-2012).pdf

916-MUMNP-2011-FORM 3(9-2-2012).pdf

916-MUMNP-2011-Form 3-191214.pdf

916-mumnp-2011-form 3.pdf

916-mumnp-2011-form 5.pdf

916-MUMNP-2011-FORM PCT-ISA-210(28-1-2014).pdf

916-MUMNP-2011-FORM PCT-ISA-210(28-12-2012).pdf

916-MUMNP-2011-FORM PCT-ISA-210(6-5-2011).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-1(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-10(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-11(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-12(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-2(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-3(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-4(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-5(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-6(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-7(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-8(28-1-2014).pdf

916-MUMNP-2011-OTHER DOCUMENT PART-9(28-1-2014).pdf

916-MUMNP-2011-PETITION UNDER RULE-137(28-12-2012).pdf

916-MUMNP-2011-PETITION UNDER RULE-137(9-9-2011).pdf

916-MUMNP-2011-REPLY TO EXAMINATION REPORT(11-8-2014).pdf

916-MUMNP-2011-REPLY TO EXAMINATION REPORT(28-1-2014).pdf

916-MUMNP-2011-REPLY TO EXAMINATION REPORT(28-12-2012).pdf

Claims _28 july 2014.pdf

Examination Report 29.7.2013.pdf

Form 2_Clean Copy - As filed.pdf

Responce Letter dated 28 July 2014.pdf


« Previous Patent
Next Patent »
Patent Number 265211
Indian Patent Application Number 916/MUMNP/2011
PG Journal Number 08/2015
Publication Date 20-Feb-2015
Grant Date 13-Feb-2015
Date of Filing 06-May-2011
Name of Patentee GLENMARK PHARMACEUTICALS S.A.
Applicant Address CHEMIN DE LA COMBETA 5, 2300 LA CHAUX-DE-FONDS, SWITZERLAND.
Inventors:
# Inventor's Name Inventor's Address
1 CHAUDHARI SACHIN SUNDARLAL 15/304, FAM C.H.S., SECTOR # 11, KOPARKHAIRANE, NAVI MUMBAI-400709, MAHARASHTRA,INDIA.
2 THOMAS ABRAHAM FLAT NO.5,11TH FLOOR, BUILDING NO.A-6 MILLENNIUM TOWERS, SECTOR 9,SANPADA, NAVI MUMBAI-400705,MAHARASHTRA, INDIA
3 PATIL NISHA PARAG B-703, GAUTAM CO-OPERATIVE SOCIETY, KAJUPADA TEKADI,ROAD, BORIVALI EAST, MUMBAI-400066,MAHARASHTRA,INDIA
4 KHAIRATKAR-JOSHI NEELIMA C-101, DEVPRAYAG CHS, BHAKTI MANDIR RD, HARI NIWAS,PANCHPAKHADI,THANE(W)-400 602, MAHARASHTRA,INDIA.
5 MUKHOPADHYAY INDRANIL INIIN];FLAT NO. F-201, MILLENNIUM PARK, PLOT 17,22,23,SECTOR-25, NED, NAVI MUMBAI-400706, MAHARASHTRA,INDIA.
PCT International Classification Number C07D 491/048, A61K 31/34, A61K 31/519
PCT International Application Number PCT/IB2009/000840
PCT International Filing date 2010-03-22
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 2213/MUM/2009 2009-09-23 India
2 61/171,355 2009-04-21 India
3 61/294,470 2010-01-12 India
4 2906/MUM/2009 2009-12-16 India
5 61/251,994 2009-10-15 India